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Antimicrobial resistance is one of our most serious health threats . Infections from resistant 
bacteria are now too common, and some pathogens have even become resistant to 
multiple types or classes of antibiotics (antimicrobials used to treat bacterial infections) . 
The loss of effective antibiotics will undermine our ability to fight infectious diseases 
and manage the infectious complications common in vulnerable patients undergoing 
chemotherapy for cancer, dialysis for renal failure, and surgery, especially organ 
transplantation, for which the ability to treat secondary infections is crucial . 
When first-line and then second-line antibiotic treatment options are limited by resistance 
or are unavailable, healthcare providers are forced to use antibiotics that may be more toxic 
to the patient and frequently more expensive and less effective . Even when alternative 
treatments exist, research has shown that patients with resistant infections are often 
much more likely to die, and survivors have significantly longer hospital stays, delayed 
recuperation, and long-term disability . Efforts to prevent such threats build on the 
foundation of proven public health strategies: immunization, infection control, protecting 
the food supply, antibiotic stewardship, and reducing person-to-person spread through 
screening, treatment and education .
Dr . Tom Frieden, MD, MPH
Director, U .S . Centers for Disease Control and Prevention
Meeting the Challenges of Drug-Resistant Diseases in Developing Countries
Committee on Foreign Affairs Subcommittee on Africa, Global Health, Human Rights,  
and International Organizations
United States House of Representatives
April 23, 2013
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ANTIBIOTIC RESISTANCE THREATS IN 
THE UNITED STATES, 2013
Executive Summary
Antibiotic Resistance Threats in the United States, 2013 is a snapshot of the complex problem 
of antibiotic resistance today and the potentially catastrophic consequences of inaction . 
The overriding purpose of this report is to increase awareness of the threat that antibiotic 
resistance poses and to encourage immediate action to address the threat . This document 
can serve as a reference for anyone looking for information about antibiotic resistance . It is 
specifically designed to be accessible to many audiences . For more technical information, 
references and links are provided .
This report covers bacteria causing severe human infections and the antibiotics used to 
treat those infections . In addition, Candida, a fungus that commonly causes serious illness, 
especially among hospital patients, is included because it, too, is showing increasing 
resistance to the drugs used for treatment . When discussing the pathogens included in this 
report, Candida will be included when referencing “bacteria” for simplicity . Also, infections 
caused by the bacteria Clostridium difficile (C. difficile) are also included in this report . 
Although C. difficile infections are not yet significantly resistant to the drugs used to treat 
them, most are directly related to antibiotic use and thousands of Americans are affected 
each year . 
Drug resistance related to viruses such as HIV and influenza is not included, nor is drug 
resistance among parasites such as those that cause malaria . These are important 
problems but are beyond the scope of this report . The report consists of multiple one or 
two page summaries of cross-cutting and bacteria- specific antibiotic resistance topics . 
The first section provides context and an overview of antibiotic resistance in the United 
States . In addition to giving a national assessment of the most dangerous antibiotic 
resistance threats, it summarizes what is known about the burden of illness, level of 
concern, and antibiotics left to defend against these infections . This first section also 
includes some basic background information, such as fact sheets about antibiotic safety 
and the harmful impact that resistance can have on high-risk groups, including those with 
chronic illnesses such as cancer . 
CDC estimates that in the United States, more than two million people are sickened every 
year with antibiotic-resistant infections, with at least 23,000 dying as a result . The estimates 
are based on conservative assumptions and are likely minimum estimates . They are the best 
approximations that can be derived from currently available data .
Regarding level of concern, CDC has — for the first time — prioritized bacteria in this report 
into one of three categories: urgent, serious, and concerning . 
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Urgent Threats
■■ Clostridium difficile 
■■ Carbapenem-resistant Enterobacteriaceae (CRE)
■■ Drug-resistant Neisseria gonorrhoeae 
Serious Threats
■■ Multidrug-resistant Acinetobacter 
■■ Drug-resistant Campylobacter
■■ Fluconazole-resistant Candida (a fungus)
■■ Extended spectrum β-lactamase producing Enterobacteriaceae (ESBLs)
■■ Vancomycin-resistant Enterococcus (VRE)
■■ Multidrug-resistant Pseudomonas aeruginosa
■■ Drug-resistant Non-typhoidal Salmonella 
■■ Drug-resistant Salmonella Typhi
■■ Drug-resistant Shigella
■■ Methicillin-resistant Staphylococcus aureus (MRSA) 
■■ Drug-resistant Streptococcus pneumoniae
■■ Drug-resistant tuberculosis
Concerning Threats
■■ Vancomycin-resistant Staphylococcus aureus (VRSA)
■■ Erythromycin-resistant Group A Streptococcus
■■ Clindamycin-resistant Group B Streptococcus
The second section describes what can be done to combat this growing threat, including 
information on current CDC initiatives . Four core actions that fight the spread of antibiotic 
resistance are presented and explained, including 1) preventing infections from occurring 
and preventing resistant bacteria from spreading, 2) tracking resistant bacteria, 3) 
improving the use of antibiotics, and 4) promoting the development of new antibiotics and 
new diagnostic tests for resistant bacteria .
The third section provides summaries of each of the bacteria in this report . These 
summaries can aid in discussions about each bacteria, how to manage infections, and 
implications for public health . They also highlight the similarities and differences among 
the many different types of infections . 
 This section also includes information about what groups such as states, communities, 
doctors, nurses, patients, and CDC can do to combat antibiotic resistance . Preventing 
the spread of antibiotic resistance can only be achieved with widespread engagement, 
especially among leaders in clinical medicine, healthcare leadership, agriculture, and public 
health . Although some people are at greater risk than others, no one can completely avoid 
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the risk of antibiotic-resistant infections . Only through concerted commitment and action 
will the nation ever be able to succeed in reducing this threat . 
A reference section provides technical information, a glossary, and additional resources . 
Any comments and suggestions that would improve the usefulness of future publications 
are appreciated and should be sent to Director, Division of Healthcare Quality Promotion, 
National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control 
and Prevention, 1600 Clifton Road, Mailstop A-07, Atlanta, Georgia, 30333 . E-mail can also 




THE THREAT OF  
ANTIBIOTIC RESISTANCE
Introduction
Antibiotic resistance is a worldwide problem . New forms of antibiotic resistance can 
cross international boundaries and spread between continents with ease . Many forms of 
resistance spread with remarkable speed . World health leaders have described antibiotic-
resistant microorganisms as “nightmare bacteria” that “pose a catastrophic threat” to people 
in every country in the world . 
Each year in the United States, at least 2 million people acquire serious infections with 
bacteria that are resistant to one or more of the antibiotics designed to treat those 
infections . At least 23,000 people die each year as a direct result of these antibiotic-resistant 
infections . Many more die from other conditions that were complicated by an antibiotic-
resistant infection . 
In addition, almost 250,000 people each year require hospital care for Clostridium difficile 
(C. difficile) infections . In most of these infections, the use of antibiotics was a major 
contributing factor leading to the illness . At least 14,000 people die each year in the United 
States from C. difficile infections . Many of these infections could have been prevented . 
Antibiotic-resistant infections add considerable and avoidable costs to the already 
overburdened U .S . healthcare system . In most cases, antibiotic-resistant infections require 
prolonged and/or costlier treatments, extend hospital stays, necessitate additional 
doctor visits and healthcare use, and result in greater disability and death compared with 
infections that are easily treatable with antibiotics . The total economic cost of antibiotic 
resistance to the U .S . economy has been difficult to calculate . Estimates vary but have 
ranged as high as $20 billion in excess direct healthcare costs, with additional costs to 
society for lost productivity as high as $35 billion a year (2008 dollars) .1
The use of antibiotics is the single most important factor leading to antibiotic resistance 
around the world . Antibiotics are among the most commonly prescribed drugs used 
in human medicine . However, up to 50% of all the antibiotics prescribed for people are 
not needed or are not optimally effective as prescribed . Antibiotics are also commonly 
used in food animals to prevent, control, and treat disease, and to promote the growth 
of food-producing animals . The use of antibiotics for promoting growth is not necessary, 
and the practice should be phased out . Recent guidance from the U .S . Food and Drug 
Administration (FDA) describes a pathway toward this goal .2 It is difficult to directly 
compare the amount of drugs used in food animals with the amount used in humans, but 
there is evidence that more antibiotics are used in food production . 
1 http://www .tufts .edu/med/apua/consumers/personal_home_5_1451036133 .pdf (accessed 8-5-2013); extrapolated from 
Roberts RR, Hota B, Ahmad I, et al . Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching 
hospital: implications for antibiotic stewardship . Clin Infect Dis . 2009 Oct 15;49(8):1175-84
2 http://www .fda .gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/UCM299624 .
pdf
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The other major factor in the growth of antibiotic resistance is spread of the resistant strains 
of bacteria from person to person, or from the non-human sources in the environment, 
including food . 
There are four core actions that will help fight these deadly infections: 
■■ preventing infections and preventing the spread of resistance 
■■ tracking resistant bacteria
■■ improving the use of today’s antibiotics
■■ promoting the development of new antibiotics and developing new diagnostic 
tests for resistant bacteria 
Bacteria will inevitably find ways of resisting the antibiotics we develop, which is why 
aggressive action is needed now to keep new resistance from developing and to prevent 





Antibiotic-resistant infections can happen anywhere. Data show that 
most happen in the general community; however, most deaths related 
to antibiotic resistance happen in healthcare settings, such as hospitals 
and nursing homes.
WHERE DO INFECTIONS HAPPEN?
CS239559
Estimated minimum number of illnesses and 
deaths caused by antibiotic resistance*:









Estimated minimum number of illnesses and 
death due to Clostridium difficile (C. difficile),  
a unique bacterial infection that, although 
not significantly resistant to the drugs used to 
treat it, is directly related to antibiotic use and 
resistance:
Simply using antibiotics creates resistance.  These drugs should only be used to treat infections.
Fertilizer or water 
containing animal feces 
and drug-resistant bacteria 








bacteria in his gut.
Drug-resistant bacteria 
in the animal feces can 
remain on crops and be 
eaten. These bacteria 




remain on meat 
from animals.  
When not handled 
or cooked properly, 




spread to other 
patients from 
surfaces within the 
healthcare facility.
Resistant germs spread 
directly to other patients or 
indirectly on unclean hands 
of healthcare providers.
George stays at 
home and in the 
general community.  
Spreads resistant 
bacteria. George gets care at a 
hospital, nursing home or 




How Antibiotic Resistance Happens
Examples of How Antibiotic Resistance Spreads
4.
Some bacteria give 
their drug-resistance to 




bacteria are now allowed to 
grow and take over.
1. 
Lots of germs.  




bacteria causing the illness, 
as well as good bacteria 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Limitations of Estimating the Burden 
of Disease Associated with Antibiotic-
Resistant Bacteria
This report uses several methods, described in the technical appendix, to estimate the 
number of cases of disease caused by antibiotic-resistant bacteria and fungi and the 
number of deaths resulting from those cases of disease . The data presented in this report 
are approximations, and totals, as provided in the national summary tables, can provide 
only a rough estimate of the true burden of illness . Greater precision is not possible at this 
time for a number of reasons: 
■■ Precise criteria exist for determining the resistance of a particular species of 
bacteria to a specific antibiotic . However, for many species of bacteria, there are 
no standard definitions that allow for neatly dividing most species into only two 
categories—resistant vs . susceptible without regard to a specific antibiotic . This 
report specifies how resistance is defined for each microorganism .
■■ There are very specific criteria and algorithms for the attribution of deaths to 
specific causes that are used for reporting vital statistics data . In general, there 
are no similar criteria for making clinical determinations of when someone’s 
death is primarily attributable to infection with antibiotic-resistant bacteria, as 
opposed to other co-existing illnesses that may have contributed to or caused 
death . Many studies attempting to determine attributable mortality rely on 
the judgment of chart reviewers, as is the case for many surveillance systems . 
Thus, the distinction between an antibiotic-resistant infection leading directly to 
death, an antibiotic-resistant infection contributing to a death, and an antibiotic-
resistant infection related to, but not directly contributing to a death are usually 
determined subjectively, especially in the preponderance of cases where patients 
are hospitalized and have complicated clinical presentations . 
In addition, the estimates provided in this report represent an underestimate of the total 
burden of bacterial resistant disease .
■■ The methodology employed in this report likely underestimates, at least for 
some pathogens, the impact of antibiotic resistance on mortality . As described 
in the technical appendix, the percentage of resistant isolates for some bacteria 
was multiplied by the total number of cases or the number of deaths ascribed 
to that bacterium . A number of studies have shown that the risk of death 
following infection with a strain of resistant bacteria is greater than that following 
infection with a susceptible strain of the same bacteria . More accurate data for 
all bacteria would be necessary to estimate the extent of the differential risk for 
death associated with a resistant infection vs . the risk of death associated with a 
susceptible infection . But, lacking that data, the lower, more conservative estimate 
has been used . That estimate is the approximation of the number of deaths derived 
by applying the proportion of resistant isolates to the estimated total number of 
deaths caused by that pathogen . 
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■■ For several pathogens, complete data from all types of infections are not 
available since tracking is limited to the more severe types of infections . For some 
pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA), only cases 
due to invasive disease are counted . For other pathogens, where resistance is 
predominately limited to healthcare settings, only disease occurring in acute care 
hospitals, or requiring hospitalization, are counted . 
The actual number of infections and the actual number of deaths, therefore, are certainly 
higher than the numbers provided in this report . 
This report does not provide a specific estimate for the financial cost of antibiotic-resistant 
infections . Although a variety of studies have attempted to estimate costs in limited 
settings, such as a single hospital or group of hospitals, the methods used are quite 
variable . Similarly, careful work has been done to estimate costs for specific pathogens, 
such as Streptococcus pneumoniae and MRSA . However, no consensus methodology 
currently exists for making such monetary estimates for many of the other pathogens listed 
in this report . For this reason, this report references non-CDC estimates in the introduction, 
but does not attempt to estimate the overall financial burden of antibiotic resistance to the 
United States . 
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Assessment of Domestic Antibiotic 
Resistance Threats
CDC conducted an assessment of antibiotic resistance threats, categorizing the threat 
level of each bacteria as urgent, serious, or concerning . The assessment was done in 
consultation with non-governmental experts in antibiotic resistance who serve on the 
Antimicrobial Resistance Working Group of the CDC Office of Infectious Diseases Board 
of Scientific Counselors (http://www .cdc .gov/oid/BSC .html) . CDC also received input and 
recommendations from the National Institutes of Health (NIH) and the U .S . Food and Drug 
Administration (FDA) . Threats were assessed according to seven factors associated with 
resistant infections: 
■■ clinical impact 
■■ economic impact
■■ incidence 
■■ 10-year projection of incidence 
■■ transmissibility 
■■ availability of effective antibiotics 
■■ barriers to prevention
The assessment was focused on domestic impact, but the threat of importing international 
antibiotic-resistant pathogens was taken into account in the 10-year incidence projection . 
Because antibiotic resistance is a rapidly evolving problem, this assessment will be revised at 
least every five years . Examples of findings that could result in a change in threat status are:
■■ Multidrug-resistant and extensively drug-resistant tuberculosis (MDR and XDR 
TB) infections are an increasing threat outside of the United States . In the United 
States, infections are uncommon because a robust prevention and control 
program is in place . If infection rates of MDR and XDR TB increase within the U .S ., 
this antibiotic-resistant threat will change from serious to urgent, because it is 
transmissible through respiratory secretions, and because treatment options are 
very limited .
■■ MRSA infections can be very serious and the number of infections is among 
the highest of all antibiotic-resistant threats . However, the number of serious 
infections is decreasing and there are multiple effective antibiotics for treating 
infections . If MRSA infection rates increase or MRSA strains become more resistant 
to other antibiotic agents, then MRSA may change from a serious to an urgent 
threat .
■■ Streptococcus pneumoniae (pneumococcus) can cause serious and sometimes 
life-threatening infections . Antibiotic resistance significantly affects the ability to 
manage these infections . A new version of the pneumococcal conjugate vaccine 
(PCV13), introduced in 2010, protects against infections with the most resistant 
pneumococcus strains and rates of resistant infections are declining . The extent to 
which this trend will continue is unknown, but a significant and sustainable drop in 
resistant infection rates could result in this threat being recategorized  
as concerning .
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In general, threats assigned to the urgent and serious categories require more monitoring 
and prevention activities, whereas the threats in the concerning category require less . 
Regardless of category, threat-specific CDC activities are tailored to meet the epidemiology 
of the infectious agent and to address any gaps in the ability to detect resistance and to 
protect against infections . 
HAZARD LEVEL
URGENT
These are high-consequence antibiotic-resistant threats because of 
significant risks identified across several criteria. These threats may not be 
currently widespread but have the potential to become so and require urgent 
public health attention to identify infections and to limit transmission.




These are significant antibiotic-resistant threats. For varying reasons (e.g., 
low or declining domestic incidence or reasonable availability of therapeutic 
agents), they are not considered urgent, but these threats will worsen 
and may become urgent without ongoing public health monitoring and 
prevention activities.
Multidrug-resistant Acinetobacter, Drug-resistant Campylobacter, Fluconazole-resistant Candida (a fungus), 
Extended spectrum β-lactamase producing Enterobacteriaceae (ESBLs), Vancomycin-resistant Enterococcus 
(VRE), Multidrug-resistant Pseudomonas aeruginosa, Drug-resistant Non-typhoidal Salmonella, Drug-resistant 
Salmonella Typhi, Drug-resistant Shigella, Methicillin-resistant Staphylococcus aureus (MRSA), Drug-resistant 
Streptococcus pneumonia, Drug-resistant tuberculosis (MDR and XDR)
HAZARD LEVEL
CONCERNING
These are bacteria for which the threat of antibiotic resistance is low, and/
or there are multiple therapeutic options for resistant infections. These 
bacterial pathogens cause severe illness. Threats in this category require 
monitoring and in some cases rapid incident or outbreak response.
Vancomycin-resistant Staphylococcus aureus (VRSA), Erythromycin-resistant Streptococcus Group A, 
Clindamycin-resistant Streptococcus Group B
Although C. difficile is not currently significantly resistant to antibiotics used to treat it, it was included in the threat assessment 
because of its unique relationship with resistance issues, antibiotic use, and its high morbidity and mortality . 
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Running Out of Drugs to Treat Serious 
Gram-Negative Infections
Among all of the bacterial resistance problems, gram-negative pathogens are particularly 
worrisome, because they are becoming resistant to nearly all drugs that would be 
considered for treatment . This is true as well, but not to the same extent, for some of 
the gram-positive infections (e .g ., Staphylococcus and Enterococcus). The most serious 
gram-negative infections are healthcare-associated, and the most common pathogens 
are Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter . Treating infections 
of either pan-resistant or nearly pan-resistant gram-negative microorganisms is an 
increasingly common challenge in many hospitals . The table below describes the drug 
classes used to treat these infections and a description of important drug resistance and 
other limitations . The classes are in order of most likely to be used to less likely to be used .
Drug Class Important Characteristics Resistance and Other Limitations
β-lactams A large class of broad-spectrum drugs 
that are the main treatment for gram-
negative infections . The subclasses are 
listed below and are presented in an 
order from narrow-spectrum (penicillins) 
to broad-spectrum (carbapenem) 
β-lactam drugs .
Gram-negative bacteria have developed 
several pathways to β-lactam resistance . 
Perhaps the most concerning are 
β-lactamases, enzymes that destroy the 
β-lactam antibiotics . Some β-lactamases 
destroy narrow spectrum drugs 
(e .g ., only active against penicillins) 
while newer β-lactamases (e .g . 
carbapenemases found in carbapenem-
resistant Enterobacteriaceae or CRE) are 







Among the first antibiotics developed 
for treatment of bacterial infections . In 
the absence of resistance, these drugs 
are active against a broad range of 
bacterial pathogens .
Resistance among gram-negative 
bacteria is widespread . These drugs are 
rarely recommended as treatment for 




These drugs are still active against gram- 
negative bacteria that have β-lactamases 
with limited activity for destroying 
β-lactam antibiotics .
These drugs are important for treatment 
of serious gram- negative infections 
but resistance is increasing . Bacteria 
that are resistant to extended-spectrum 
cephalosporins and carbapenems are 
usually resistant to these drugs as well . 
New β-lactamase inhibitor combination 
drugs in development have the 
potential to overcome some, but not 
all, of resistance from the most potent 




These drugs have been a cornerstone 
for treatment of serious gram-negative 
infections for the past 20 years . 
Resistant gram-negative infections first 
emerged in healthcare settings but now 
are also spreading in the community . 
When resistance occurs, a carbapenem 
is the only remaining β-lactam agent .
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Drug Class Important Characteristics Resistance and Other Limitations
Carbapenems A broad-spectrum β-lactam antibiotic 
that is considered the last resort for 
treatment of serious gram-negative 
infections . 
CRE infections are spreading in 
healthcare facilities throughout the 
United States and the world . It is 
reasonable to expect that this resistance 
will expand to bacteria that circulate 
in the community, as witnessed by 
extended-spectrum β-lactamase 
producing bacteria . Carbapenem 
resistance can also be found among 
other gram-negative bacteria including 
Pseudomonas and Acinetobacter spp. 
Once bacteria become resistant to 
carbapenems, they are usually resistant 
to all β-lactams . 
Fluoroquinolones These are broad-spectrum antibiotics 
that are often given orally, making them 
convenient to use in both inpatients and 
outpatients .
Resistant bacteria develop quickly with 
increased use in a patient population . 
Increased use is also associated with 
an increase in infections caused by 
fluoroquinolone-resistant, hyper-
virulent strains of Clostridium difficile . 
Aminoglycosides These drugs are often used in 
combination with β-lactam drugs for 
the treatment of serious gram-negative 
infections .
Despite growing resistance problems, 
these drugs continue to be an 
important therapeutic option . However, 
clinicians rarely use these drugs alone 




Tetracyclines are not a first-line 
treatment option for serious gram 
negative infections; however, with 
increasing resistance to other drug 
classes, tetracyclines are considered 
as a treatment option . Glycyclines (i .e ., 
tigecycline) are often considered for 
treatment of multidrug-resistant gram-
negative infections .
Tigecycline is a drug that does not 
distribute evenly in the body, so it is 
often used in combination with other 
drugs depending upon the site of 
infection . Resistance to tigecycline 
has emerged but it is still relatively 
uncommon .
Polymyxins These drugs are an older class that fell 
out of favor because of toxicity concerns . 
Now they are often used as a “last resort” 
agent for treatment of multidrug-
resistant gram-negative infections . 
Because these are generic drugs, there 
are limited contemporary data on 
proper dosing . In addition, resistance 
is emerging, but there are limited data 
guiding the accurate detection of 
resistance in hospital labs . As a result, 
use of these drugs present significant 
challenges for clinicians . In the absence 
of a drug sponsor, FDA and NIH are 
funding studies to fill these critical 
information gaps . 
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People at Especially High Risk
As antibiotic resistance grows, the antibiotics used to treat infections do not work as well 
or at all . The loss of effective antibiotic treatments will not only cripple the ability to fight 
routine infectious diseases but will also undermine treatment of infectious complications 
in patients with other diseases . Many of the advances in medical treatment—joint 
replacements, organ transplants, cancer therapy, and treatment of chronic diseases such as 
diabetes, asthma, rheumatoid arthritis—are dependent on the ability to fight infections with 
antibiotics . If that ability is lost, the ability to safely offer people many life-saving and life-
improving modern medical advantages will be lost with it . For example:
CANCER CHEMOTHERAPY
People receiving chemotherapy are often at risk for developing an infection when 
their white blood cell count is low. For these patients, any infection can quickly 
become serious and effective antibiotics are critical for protecting the patient 
from severe complications or death.
COMPLEX SURGERY
Patients who receive cardiac bypass, joint replacements, and other complex surgeries 
are at risk of a surgical site infection (SSI). These infections can make recovery from 
surgery more difficult because they can cause additional illness, stress, cost, and 
even death. For some, but not all surgeries, antibiotics are given before surgery to 
help prevent infections.
RHEUMATOID ARTHRITIS
Inflammatory arthritis affects the immune system, which controls how well the 
body fights off infections. People with certain types of arthritis have a higher risk 
of getting infections. Also, many medications given to treat inflammatory arthritis 
can weaken the immune system. Effective antibiotics help ensure that arthritis 
patients can continue to receive treatment.
DIALYSIS FOR END-STAGE RENAL DISEASE
Patients who undergo dialysis treatment have an increased risk for getting a 
bloodstream infection. In fact, bloodstream infections are the second leading 
cause of death in dialysis patients. Infections also complicate heart disease, 
the leading cause of death in diaysis patients. Infection risk is higher in 
these patients because they have weakened immune systems and often require 
catheters or needles to enter their bloodstream. Effective antibiotics help 
ensure that dialysis patients can continue to receive life-saving treatment.
ORGAN AND BONE MARROW TRANSPLANTS
Transplant recipients are more vulnerable to infections. Because a patient 
undergoes complex surgery and receives medicine to weaken the immune system 
for a year or more, the risk of infection is high. It is estimated that 1% of organs 
transplanted in the United States each year carry a disease that comes from the 




1         5
ANTIBIOTICS ARE RESPONSIBLE  
FOR ALMOST
OUT OF
EMERGENCY DEPARTMENT VISITS 
FOR ADVERSE DRUG EVENTS
ANTIBIOTICS ARE THE 
MOST COMMON CAUSE OF  
EMERGENCY DEPARTMENT VISITS  
FOR ADVERSE DRUG EVENTS  
IN CHILDREN UNDER  
18 YEARS OF AGE.
■■ Antibiotics are powerful drugs that are generally safe and very helpful in fighting 
disease, but there are times when antibiotics can actually be harmful .
■■ Antibiotics can have side effects, including allergic reactions and a potentially 
deadly diarrhea caused by the bacteria Clostridium difficile (C. difficile). Antibiotics 
can also interfere with the action of other drugs a patient may be taking for 
another condition . These unintended reactions to antibiotics are called adverse 
drug events .
■■ When someone takes an antibiotic that they do not need, they are needlessly 
exposed to the side effects of the drug and do not get any benefit from it .
■■ Moreover, taking an antibiotic when it is not needed can lead to the development 
of antibiotic resistance . When resistance develops, antibiotics may not be able to 
stop future infections . Every time someone takes an antibiotic they don’t need, 
they increase their risk of developing a resistant infection in the future .  
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Types of Adverse Drug Events Related to 
Antibiotics
Allergic Reactions
Every year, there are more than 140,000 emergency department visits for 
reactions to antibiotics . Almost four out of five (79%) emergency department 
visits for antibiotic-related adverse drug events are due to an allergic reaction . 
These reactions can range from mild rashes and itching to serious blistering skin 
reactions swelling of the face and throat, and breathing problems . Minimizing 
unnecessary antibiotic use is the best way to reduce the risk of adverse drug 
events from antibiotics . Patients should tell their doctors about any past drug 
reactions or allergies . 
C. difficile
C. difficile causes diarrhea linked to at least 14,000 American deaths each year . 
When a person takes antibiotics, good bacteria that protect against infection are 
destroyed for several months . During this time, patients can get sick from C. difficile 
picked up from contaminated surfaces or spread from a healthcare provider’s 
hands . Those most at risk are people, especially older adults, who take antibiotics 
and also get medical care . Take antibiotics exactly and only as prescribed . 
Drug Interactions and Side Effects
Antibiotics can interact with other drugs patients take, making those drugs or the 
antibiotics less effective . Some drug combinations can worsen the side effects of 
the antibiotic or other drug . Common side effects of antibiotics include nausea, 
diarrhea, and stomach pain . Sometimes these symptoms can lead to dehydration 
and other problems . Patients should ask their doctors about drug interactions and 
the potential side effects of antibiotics . The doctor should be told immediately if a 
patient has any side effects from antibiotics .
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GAPS IN KNOWLEDGE  
OF ANTIBIOTIC RESISTANCE
LIMITED NATIONAL, STATE, AND FEDERAL CAPACITY TO DETECT 
AND RESPOND TO URGENT AND EMERGING ANTIBIOTIC 
RESISTANCE THREATS
Even for critical pathogens of concern like carbapenem-
resistant Enterobacteriaceae (CRE) and Neisseria gonorrhoeae, 
we do not have a complete picture of the domestic incidence, 
prevalence, mortality, and cost of resistance.
CURRENTLY, THERE IS NO SYSTEMATIC INTERNATIONAL 
SURVEILLANCE OF ANTIBIOTIC RESISTANCE THREATS
Today, the international identification of antibiotic 
resistance threats occurs through domestic importation of 
novel antibiotic resistance threats or through identification 
of overseas outbreaks.
DATA ON ANTIBIOTIC USE IN HUMAN HEALTHCARE AND IN 
AGRICULTURE ARE NOT SYSTEMATICALLY COLLECTED
Routine systems of reporting and benchmarking antibiotic 
use wherever it occurs need to be piloted and scaled 
nationwide.
PROGRAMS TO IMPROVE ANTIBIOTIC PRESCRIBING ARE NOT 
WIDELY USED IN THE UNITED STATES
These inpatient and outpatient programs hold great promise 
for reducing antibiotic resistance threats, improving patient 
outcomes, and saving healthcare dollars.
ADVANCED TECHNOLOGIES CAN IDENTIFY THREATS MUCH 
FASTER THAN CURRENT PRACTICE
Advanced molecular detection (AMD) technologies, which can 
identify AR threats much faster than current practice, are not 






Timeline of Key Antibiotic Resistance Events
Dates are based upon early reports 
of resistance in the literature. In the 
case of pan drug-resistant (PDR)-
Acinetobacter and Pseudomonas, 
the date is based upon reports 
of healthcare transmission or 
outbreaks.  Note: penicillin was in 
limited use prior to widespread 






 penicillin-R pneumococcus 1965
 erythromycin-R Streptococcus 1968
 gentamicin-R Enterococcus 1979
 ceftazidime-R Enterobacteriaceae 1987
 vancomycin-R Enterococcus 1988
 levofloxacin-R pneumococcus 1996
 imipenem-R Enterobacteriaceae 1998
 XDR tuberculosis 2000
 linezolid-R Staphylococcus 2001
 vancomycin-R Staphylococcus 2002
 PDR-Acinetobacter and Pseudomonas 2004/5
 ceftriaxone-R Neisseria gonorrhoeae 2009
 PDR-Enterobacteriaceae 


















FIGHTING BACK AGAINST  
ANTIBIOTIC RESISTANCE
Four Core Actions to Prevent  
Antibiotic Resistance
1 PREVENTING INFECTIONS,PREVENTING THE SPREAD OF RESISTANCE
Avoiding infections in the first place reduces the amount of 
antibiotics that have to be used and reduces the likelihood that 
resistance will develop during therapy. There are many ways that 
drug-resistant infections can be prevented: immunization, safe 
food preparation, handwashing, and using antibiotics as directed 
and only when necessary. In addition, preventing infections also 
prevents the spread of resistant bacteria.
TRACKING
CDC gathers data on antibiotic-resistant infections, causes of 
infections and whether there are particular reasons (risk factors) 
that caused some people to get a resistant infection. With that 
information, experts can develop specific strategies to prevent 
those infections and prevent the resistant bacteria from spreading.
2
3 IMPROVING ANTIBIOTIC PRESCRIBING/STEWARDSHIPPerhaps the single most important action needed to greatly slow 
down the development and spread of antibiotic-resistant infections 
is to change the way antibiotics are used. Up to half of antibiotic 
use in humans and much of antibiotic use in animals is unnecessary 
and inappropriate and makes everyone less safe. Stopping even 
some of the inappropriate and unnecessary use of antibiotics in 
people and animals would help greatly in slowing down the spread 
of resistant bacteria. This commitment to always use antibiotics 
appropriately and safely—only when they are needed to treat 
disease, and to choose the right antibiotics and to administer them 
in the right way in every case—is known as antibiotic stewardship.
4 DEVELOPING NEW DRUGS AND DIAGNOSTIC TESTSBecause antibiotic resistance occurs as part of a natural process in 
which bacteria evolve, it can be slowed but not stopped. Therefore, 
we will always need new antibiotics to keep up with resistant 








IMPROVING USE OF 
ANTIBIOTICS.
DEVELOPING NEW ANTIBIOTICS 
AND DIAGNOSTIC TESTS. 
1. PREVENTING INFECTIONS, 
PREVENTING THE SPREAD OF 
RESISTANCE
Preventing infections from developing reduces 
the amount of antibiotics used . This reduction in 
antibiotic use, in turn, slows the pace of antibiotic 
resistance . Preventing infections also prevents the 
spread of resistant bacteria . Antibiotic-resistant infections can 
be prevented in many ways . This section focuses on CDC’s 
works to prevent antibiotic-resistant infections in healthcare settings, in the community, 
and in food . 
CDC’s Work to Prevent Infections and Antibiotic Resistance in Healthcare 
Settings
Antibiotic resistance in healthcare settings is a significant threat to public health . Because 
almost all Americans will receive care in a medical setting at some point, the problem 
can affect anyone . In addition, many times, patients in medical settings such as hospitals 
and long-term care facilities (e .g ., skilled nursing facilities and nursing homes) are already 
vulnerable due to weak immune systems and underlying illness . For these patients, 
contracting an antibiotic-resistant infection is especially dangerous . By preventing 
antibiotic resistance in healthcare settings, patients’ lives are better protected and their 
health can be better preserved . In addition, healthcare facilities, systems, insurers and 
patients can save dollars that otherwise would have been spent on more complex care and 
medications needed to manage antibiotic-resistant infections . 
CDC works to prevent antibiotic resistance in healthcare settings by providing a system to 
track resistance and prescribing patterns at national, regional, and local levels; providing 
guidance to healthcare facilities interested in better antibiotic use; and working to prevent 
all patient infections through infection control guidelines, assistance implementing these 
guidelines, and laboratory expertise . Here are some examples of how CDC is working to 
prevent antibiotic resistance in healthcare settings:
Tracking
CDC’s National Healthcare Safety Network (NHSN) is used by healthcare facilities to 
electronically report infections, antibiotic use, and resistance . Data currently submitted by 
hospitals to NHSN allow facilities, states, and regions the ability to track and benchmark 
antibiotic resistance in bacteria responsible for many healthcare-associated infections . As 
more hospitals submit data to the new NHSN Antibiotic Use and Resistance Module, they 
will be able to track and benchmark antibiotic resistance in all bacteria, as well as track 
antibiotic usage . This information will allow facilities to target areas of concern, to make 
needed improvements and to track the success of their efforts . In addition, NHSN allows 
CDC to perform and report national assessments of antibiotic resistance . 
CDC’s specialized, national reference laboratory tests bacteria samples from around the 
country to detect new and emerging resistance patterns that affect patient health . This 
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reference testing also provides an early warning of new resistance that has the potential to 
spread across the nation and that requires public health action .
Additionally, CDC recently conducted a survey in collaboration with its Emerging 
Infections Program to estimate the number of healthcare-associated infections and to 
better understand antibiotic use among inpatients in U .S . hospitals . The survey found that 
antibiotic use was frequent, that most antibiotic use was for treating active infections, and 
that vancomycin was the most commonly used antibiotic overall . Formal results are due to 
be published in late 2013 and 2014 . CDC plans to conduct a repeat survey in 2014 that will 
include assessments of appropriate antibiotic prescribing .
Improving Antibiotic Prescribing
CDC manages the Get Smart program, a national campaign to improve antibiotic 
prescribing and use in both outpatient and inpatient settings . The program supports a 
variety of state-based programs modeled on the national effort . Each November, CDC 
publicizes its annual Get Smart About Antibiotics Week to raise awareness among patients, 
healthcare providers, hospital administrators, and policy makers about the threat of 
antibiotic resistance and the need to decrease inappropriate antibiotic use . CDC provides 
public health messages and resources for improving antibiotic use in healthcare settings 
and is now working with a variety of partners to improve the use of antibiotics in healthcare 
settings . One core activity is the development and implementation of the Antibiotic 
Stewardship Drivers and Change Package, a tool that provides healthcare facilities with 
a menu of interventions they can select from to improve antibiotic use . CDC developed 
and tested this tool with the Institute for Healthcare Improvement . Additional information 
about Get Smart About Antibiotics Week activities and messages can be found on CDC’s 
website: http://www .cdc .gov/getsmart/ . The Drivers and Change Package can be found at 
http://www .cdc .gov/getsmart/healthcare/improve-efforts/driver-diagram/index .html .
Protecting Patients from Infections
Preventing infections negates the need for antibiotic use in the first place, and scientific 
evidence shows that reducing antibiotic use in a single facility can reduce resistance 
in that facility . Taken on a national scale, infection prevention efforts can significantly 
decrease resistance . To help prevent infections, CDC conducts research to find new ways of 
preventing infections; provides the nation with infection prevention guidelines and tools to 
prevent infections; serves as the nation’s reference laboratory to identify microorganisms; 
and offers the nation’s largest healthcare-associated infection tracking system, NHSN, 
allowing facilities and states to identify and address problem areas .
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CDC’s Work to Prevent Antibiotic Resistance in the Community
Antibiotic-resistant infections outside of the hospital setting were rare until recently . 
Today, resistant infections that can be transmitted in the community include tuberculosis 
and respiratory infections caused by Streptococcus pneumoniae, skin infections caused by 
methicillin-resistant Staphylococcus aureus, and sexually transmitted infections such as 
gonorrhea .
CDC works to prevent antibiotic resistance in the community by providing systems to track 
infections and changes in resistance; improving prescribing at national, regional, and local 
levels; and limiting or interrupting the spread of infections . These activities are similar to 
the strategies used in medical settings, but the approach can differ because the population 
(potentially everyone) is large and the settings are different . Here are some examples of the 
strategies CDC uses to prevent antibiotic resistance in communities:
Tracking Community Infections and Resistance
These programs are examples of CDC’s effort to identify critical infections in the community 
and monitor resistance trends .
■■ Active Bacterial Core surveillance (ABCs): Tracking infections caused by Neisseria 
meningitidis, Streptococcus pneumoniae, Groups A and B Streptococcus, and 
methicillin-resistant Staphylococcus aureus
■■ Gonococcal Isolate Surveillance Project (GISP): Collecting isolates from 
gonorrhea infections to monitor antibiotic resistance
■■ National Tuberculosis Surveillance System (NTSS): National Electronic Disease 
Surveillance System (NEDSS)-based reporting of tuberculosis cases including 
resistance data
■■ Healthcare-Associated Infections-Community Interface (HAIC): Tracking 
infections with C. difficile and with multidrug-resistant gram-negative 
microorganisms .
Improving Antibiotic Prescribing
Prescribing antibiotics when they are not needed or prescribing the wrong antibiotic in 
outpatient settings such as doctors’ offices is common . In some cases, doctors might not 
order laboratory tests to confirm that bacteria are causing the infection, and therefore the 
antibiotic might be unnecessarily prescribed . In other cases, patients demand treatment 
for conditions such as a cold when antibiotics are not needed and will not help . Likewise, 
healthcare providers can be too willing to satisfy a patient’s expectation for an antibiotic 
prescription . CDC manages the Get Smart program, a national campaign to improve 
antibiotic prescribing and use in both outpatient and inpatient settings, and supports a 
variety of state-based programs modeled on the national effort . CDC provides local public 
health authorities with messages and resources for improving antibiotic use in outpatient 
settings and is now working with a variety of partners to identify new approaches for 
improving antibiotic use .
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Limiting and Interrupting the Spread of Antibiotic-Resistant Infections in  
the Community
Preventing the spread of infection in the community is a significant challenge, and  
many prevention interventions are used, depending on the type of infection and the route 
of transmission . 
Here are some examples of CDC’s activities to limit and interrupt the spread of antibiotic-
resistant community infections:
■■ Contact Tracing: A prevention strategy that has proven successful is tracking cases 
(individuals who are infected) and tracing contacts (people who have had contact 
with a case that puts them at risk for infection as well) . This process is used to 
ensure that all persons requiring an intervention such as treatment, prophylaxis, 
or temporary isolation from the general public are identified and managed 
appropriately . This approach is resource intensive, but it has successfully limited 
transmission of infections including tuberculosis, gonorrhea, and meningococcus .
■■ Vaccination: There are few vaccines for antibiotic-resistant bacteria, but the S. 
pneumoniae vaccine has proven that an effective vaccine can reduce antibiotic 
resistance rates . The vaccine targets certain types of the bacteria, even if it is a 
resistant type, and reduces the overall number of infections, including those that 
are caused by resistant strains . The first version of the vaccine was introduced in 
2000 and reduced the frequency of antibiotic-resistant infections, but it did not 
protect against a particular strain of S. pneumoniae called serotype 19A . This strain 
became increasingly resistant to antibiotics and caused more infections because 
the vaccine did not offer protection . A new version of the vaccine, approved 
for use in 2010, protects against serotype 19A . As a result, the rate of resistant 
pneumococcal infections is decreasing .
■■ Treatment Guidelines: The spread of antibiotic resistance can be prevented if 
infections are effectively treated before the pathogen is spread to others . For some 
infections, laboratory tests for guiding treatment are not easily available or the 
turn-around time is slow or incomplete . This is the case for treating gonorrhea 
and tuberculosis . For these infections, healthcare providers rely on treatment 
guidelines for proper management of infections . CDC monitors resistance trends 
in Neisseria gonorrhoeae (the cause of gonorrhea) and Mycobacterium tuberculosis 
(the cause of tuberculosis) and publishes treatment guidelines to limit the 
progression of these diseases and the spread of bacteria .
■■ Promotion of Safe Sex: Increases in the spread of drug-resistant Neisseria 
gonorrhoeae poses unique challenges . To prevent transmission of this infection, 
CDC works to promote safer sexual behaviors such as abstinence, mutual 
monogamy, and correct and consistent condom use .
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Preventing Infections: CDC’s Work to Prevent Antibiotic Resistance in Food 
Each year, millions of people in the United States become sick from foodborne and other 
enteric (gastrointestinal) infections . While many of these infections are mild and do not 
require treatment, antibiotics can be lifesaving in severe infections . Antibiotic resistance 
compromises our ability to treat these infections and is a serious threat to public health . 
Preventing resistant enteric infections requires a multifaceted approach and partnerships 
because bacteria that cause some infections, such as salmonellosis and campylobacteriosis, 
have animal reservoirs, while other bacteria, such as those that cause shigellosis and 
typhoid fever, have human reservoirs . To prevent antibiotic-resistant foodborne infections, 
CDC works closely with state and local health departments; with the U .S . Food and Drug 
Administration (FDA), which regulates antibiotics, many foods, animal feed, and other 
products; and with the U .S . Department of Agriculture (USDA), which regulates meat, 
poultry, and egg products .
Tracking Antibiotic Resistance
In 1996, the National Antimicrobial Resistance Monitoring System (NARMS) was established 
as a collaboration among CDC, FDA, USDA, and state and local public health departments . 
This national public health surveillance system tracks antibiotic resistance among 
Salmonella, Campylobacter, and other bacteria transmitted commonly through food . 
NARMS tests bacteria from humans (CDC), retail meats (FDA), and food-producing animals 
(USDA) in the United States . The primary objectives of the NARMS program are to:
■■ Monitor trends in antibiotic resistance among enteric bacteria from humans, retail 
meats, and food-producing animals .
■■ Disseminate information on antibiotic resistance to promote interventions that 
reduce antibiotic resistance among foodborne bacteria .
■■ Conduct research to better understand the emergence, persistence, and spread of 
antibiotic resistance .
■■ Provide data that assist the FDA in making decisions about approving safe and 
effective antibiotic drugs for animals .
The CDC reference laboratory conducts antibiotic susceptibility testing on isolates from 
sporadic cases and outbreaks of illness . The lab also confirms and studies bacteria that 
have new antibiotic resistance patterns . NARMS provides information about patterns of 
emerging resistance among enteric pathogens to stakeholders, including federal regulatory 
agencies, policymakers, consumer advocacy groups, industry, and the public, to guide 
public health prevention and policy efforts that protect people from resistant infections . For 
more information about NARMS: www .cdc .gov/narms .
Improving Antibiotic Use
Antibiotics are widely used in food-producing animals, and according to data published 
by FDA, there are more kilograms of antibiotics sold in the United States for food-
producing animals than for people . (http://www .fda .gov/downloads/ForIndustry/UserFees/
AnimalDrugUserFeeActADUFA/UCM338170 .pdf) . This use contributes to the emergence 
of antibiotic-resistant bacteria in food-producing animals . Resistant bacteria in food-
producing animals are of particular concern because these animals serve as carriers . 
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Resistant bacteria can contaminate the foods that come from those animals, and people 
who consume these foods can develop antibiotic-resistant infections . Antibiotics must 
be used judiciously in humans and animals because both uses contribute to not only the 
emergence, but also the persistence and spread of antibiotic-resistant bacteria . 
Scientists around the world have provided strong evidence that antibiotic use in food-
producing animals can harm public health through the following sequence of events:
■■ Use of antibiotics in food-producing animals allows antibiotic-resistant bacteria to 
thrive while susceptible bacteria are suppressed or die .
■■ Resistant bacteria can be transmitted from food-producing animals to humans 
through the food supply .  
■■ Resistant bacteria can cause infections in humans . 
■■ Infections caused by resistant bacteria can result in adverse health consequences 
for humans .
Because of the link between antibiotic use in food-producing animals and the occurrence 
of antibiotic-resistant infections in humans, antibiotics should be used in food-producing 
animals only under veterinary oversight and only to manage and treat infectious diseases, 
not to promote growth . CDC encourages and supports efforts to minimize inappropriate 
use of antibiotics in humans and animals, including FDA’s strategy to promote the 
judicious use of antibiotics that are important in treating humans (http://www .fda .gov/
AnimalVeterinary/SafetyHealth/AntimicrobialResistance/JudiciousUseofAntimicrobials/
default .htm) . CDC supports FDA’s plan to implement draft guidance in 2013 that 
will operationalize this strategy (http://www .fda .gov/downloads/AnimalVeterinary/
GuidanceComplianceEnforcement/GuidanceforIndustry/UCM299624 .pdf) . CDC has also 
contributed to a training curriculum for veterinarians on prudent antibiotic use in animals . 
CDC’s efforts to improve antibiotic prescribing in humans are described in other sections of 
this report .
Preventing Infections
Efforts to prevent foodborne and other enteric infections help to reduce both antibiotic-
resistant infections and antibiotic-susceptible infections (those that can be treated 
effectively with antibiotics) . CDC activities that help prevent these infections include: 
■■ Estimating how much foodborne illness occurs . 
■■ Monitoring trends in foodborne infections .
■■ Investigating outbreaks and sporadic cases of foodborne illness to stop outbreaks 
and improve prevention .
■■ Attributing illnesses to specific foods and settings .
■■ Tracking and responding to changes in resistance .
■■ Determining the sources of antibiotic-resistant enteric infections . 
■■ Educating consumers and food workers about safe food handling practices . 
■■ Identifying and educating groups at high risk for infection .
■■ Promoting proper handwashing .
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■■ Strengthening the capacity of state and local health departments to detect, 
respond to, and report foodborne infections .
■■ Developing better diagnostic tools to rapidly and accurately find sources of 
contamination .










2. TRACKING RESISTANCE 
PATTERNS 
CDC gathers data on antibiotic-resistant infections, 
causes of infections, and whether there are 
particular reasons (risk factors) that caused some 
people to get a resistant infection . With that 
information, experts develop specific strategies to prevent 
those infections and prevent the resistant bacteria from 
spreading .
CDC’s Antibiotic Resistance and Antibiotic-Resistant Infections Tracking Platform
provides access to bacterial and fungal 
samples for testing and detailed clinical 
case data
The three main programs within EIP 
collect different types of resistance data:
■■ ABCs provides clinical 
information and resistance 
data for bacteria that cause 
infections predominately in the 
community  
■■ The HAIC provides clinical 
information and resistance data 
for bacteria and fungi that cause 
infections at the intersection 
of healthcare and the general 
community
■■ FoodNet supplies clinical and 
epidemiologic data on some 


















A national public health surveillance 
system that tracks changes in the 
susceptibility of foodborne and other 
enteric bacteria to antibiotics of human 
and veterinary medical importance  
NARMS is a collaboration among CDC, 
FDA, USDA, and state and local health 
departments  CDC tests bacterial  
isolates from humans, while FDA and 





Tracking Networks Data Collected Resistant Bacteria/Fungus3
EIP
Emerging Infections Program
There are three main programs 
within the EIP:





■■ FoodNet: Foodborne 
Diseases Active 
Surveillance Network
A network of public health-academic-






IMPROVING USE OF 
ANTIBIOTICS.
DEVELOPING NEW ANTIBIOTICS 
AND DIAGNOSTIC TESTS. 
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Tracking Networks Data Collected Resistant Bacteria/Fungus3
NHSN
National Healthcare Safety 
Network
A system that collects and provides data 
on infections and drug-resistance in 
healthcare settings . Since NHSN collects 
data directly from healthcare facilities, 
it can provide facility-level information 
on healthcare-associated infections and 









Gonococcal Isolate Surveillance 
Program
A program to track antibiotic resistance 
data for gonococcal isolates . Isolates 
are collected from sexually transmitted 





National Electronic Disease Surveillance 
System (NEDSS)-based reporting of 
tuberculosis cases including resistance 
data . Public health departments from 50 
states and the US territories contribute 
data .
Mycobacterium tuberculosis
3ABCs also includes surveillance for Neisseria meningitidis and Haemophilus influenzae. NARMS also includes surveillance for  







IMPROVING USE OF 
ANTIBIOTICS.
DEVELOPING NEW ANTIBIOTICS 
AND DIAGNOSTIC TESTS. 
3. ANTIBIOTIC STEWARDSHIP:  
IMPROVING PRESCRIBING  
AND USE
Antibiotics were first used to treat serious infections 
in the 1940s . Since then, antibiotics have saved 
millions of lives and transformed modern medicine . 
During the last 70 years, however, bacteria have 
shown the ability to become resistant to every antibiotic that 
has been developed . And the more antibiotics are used, the 
more quickly bacteria develop resistance (see the Antibiotic Resistance Timeline in this report). 
Anytime antibiotics are used, this puts biological pressure on bacteria that promotes the 
development of resistance . When antibiotics are needed to prevent or treat disease, they 
should always be used . But research has shown that as much as 50% of the time, antibiotics 
are prescribed when they are not needed or they are misused (for example, a patient is given 
the wrong dose) . This not only fails to help patients; it might cause harm . Like every other 
drug, antibiotics have side effects and can also interact or interfere with the effects of other 
medicines . This inappropriate use of antibiotics unnecessarily promotes antibiotic resistance . 
Antibiotics are a limited resource . The more that antibiotics are used today, the less likely 
they will still be effective in the future . Therefore, doctors and other health professionals 
around the world are increasingly adopting the principles of responsible antibiotic use, 
often called antibiotic stewardship . Stewardship is a commitment to always use antibiotics 
only when they are necessary to treat, and in some cases prevent, disease; to choose 
the right antibiotics; and to administer them in the right way in every case . Effective 
stewardship ensures that every patient gets the maximum benefit from the antibiotics, 
avoids unnecessary harm from allergic reactions and side effects, and helps preserve the 
life-saving potential of these drugs for the future . Efforts to improve the responsible use 
of antibiotics have not only demonstrated these benefits but have also been shown to 
improve outcomes and save healthcare facilities money in pharmacy costs .
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New England Journal of Medicine
The frequency with which doctors prescribe antibiotics varies greatly from state to 
state. The reasons for this variation are being studied and might suggest areas where 




IN YOUR FACILITY WILL
DECREASE INCREASE
■ ANTIBIOTIC RESISTANCE
■ C. DIFFICILE INFECTIONS
■ COSTS
■  GOOD PATIENT  
OUTCOMES
PROMOTE ANTIBIOTIC BEST PRACTICES— 
A FIRST STEP IN ANTIBIOTIC STEWARDSHIP
■  ENSURE ALL ORDERS HAVE DOSE, DURATION, AND INDICATIONS
■  GET CULTURES BEFORE STARTING ANTIBIOTICS
■  TAKE AN “ANTIBIOTIC TIMEOUT” REASSESSING ANTIBIOTICS 
AFTER 48–72 HOURS
ANTIBIOTIC STEWARDSHIP PROGRAMS ARE  
A “WIN-WIN” FOR ALL INVOLVED
A UNIVERSITY OF MARYLAND STUDY SHOWED 
ONE ANTIBIOTIC STEWARDSHIP PROGRAM 
SAVED A TOTAL OF $17 MILLION 
OVER EIGHT YEARS
ANTIBIOTIC STEWARDSHIP HELPS IMPROVE 
PATIENT CARE AND SHORTEN 
HOSPTIAL STAYS, THUS BENEFITING 







IMPROVING USE OF 
ANTIBIOTICS.
DEVELOPING NEW 
ANTIBIOTICS AND DIAGNOSTIC 
TESTS. 
4. DEVELOPING NEW ANTIBIOTICS 
AND DIAGNOSTIC TESTS
Because antibiotic resistance occurs as part of a 
natural evolution process, it can be significantly 
slowed but not stopped. Therefore, new antibiotics 
will always be needed to keep up with resistant 
bacteria as well as new diagnostic tests to track the 
development of resistance.
Tomorrow’s Antibiotics: The Drug Pipeline
The number of new 
antibiotics developed 
and approved has 
steadily decreased in 
the past three decades, 
leaving fewer options to 
treat resistant bacteria.
Number of Antibacterial New Drug Application (NDA)  
Approvals vs. Year Intervals*
*Intervals from 1980–2009 are 5-year intervals; 2010–2012 is a 3-year interval. Drugs are limited to systemic agents.
Data courtesy of FDA’ s Center for Drug Evaluation and Research (CDER).
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This is a combination of two drugs that can be used to 
treat gram-positive infections . Because side effects are 
common, this drug is usually not a first choice for therapy . 
Resistance in target pathogens has been described, but the 




Moxifloxacin, like other fluoroquinolones, demonstrates 
broad spectrum activity, and it can be used to treat a 
range of infections . Unfortunately, there is cross-resistance 
among the fluoroquinolones, and resistance is increasing 
in all targeted pathogens, especially Enterobacteriaceae .
Linezolid 2000 Staphylococcus
Enterococcus
Linezolid can be used to treat serious gram-positive 





Ertapenem is a carbapenem that can be used to treat a 
wide range of infections . Dissemination of carbapenem-




Gemifloxacin is a fluoroquinolone that can be used to 
treat mild to moderate community-associated respiratory 
disease . Like moxifloxacin, there is cross-resistance with 




Daptomycin is often used for treatment of serious gram-
positive infections . Resistance is emerging in all of the 






Tigecycline is often one of the only active agents for 
carbapenem-resistant gram-negative infections, and 
resistance is emerging . However, even in the absence of 
resistance, the effectiveness of this agent for treatment of 






Doripenem is a carbapenem drug most commonly used 
to treat serious gram-negative infections . Dissemination of 
carbapenem-resistant gram-negative pathogens like CRE is 




Telavancin is approved for treatment of gram-positive 
skin and soft tissue infections . Use is limited because it is 
administered intravenously and is therefore difficult to use 
in an outpatient setting . In addition, it should not be used 










Ceftaroline is a cephalosporin drug, but unlike other 
cephalosporins, this one can be used to treat MRSA 
infections . Resistance has been identified but is rare . 
Ceftaroline does not demonstrate any enhanced activity 
compared to other cephalosporins for Enterobacteriaceae . 
ESBL-producing isolates and CRE isolates are resistant to 
this drug as well . ESBL (extended-spectrum β-lactamase) 
is an enzyme that allows bacteria to become resistant to 
a wide variety of penicillins and cephalosporins  .Bacteria 







CURRENT ANTIBIOTIC RESISTANCE 
THREATS IN THE UNITED STATES,  
BY MICROORGANISM
This section includes summaries for each microorganism, 
grouped by threat level: URGENT, SERIOUS, and CONCERNING. 
50
MICROORGANISMS WITH  






These bacteria are immediate public 









IN EXCESS MEDICAL COSTS PER YEAR
THREAT LEVEL
URGENT
This bacteria is an immediate public health threat  
that requires urgent and aggressive action.
Clostridium difficile (C. difficile) causes life-threatening diarrhea. 
These infections mostly occur in people who have had both 
recent medical care and antibiotics. Often, C. difficile infections 
occur in hospitalized or recently hospitalized patients.
RESISTANCE OF CONCERN
■■ Although resistance to the antibiotics used to treat C. difficile infections 
is not yet a problem, the bacteria spreads rapidly because it is naturally 
resistant to many drugs used to treat other infections. 
■■ In 2000, a stronger strain of the bacteria emerged. This strain is resistant 
to fluoroquinolone antibiotics, which are commonly used to treat other 
infections.
■■ This strain has spread throughout North America and Europe, infecting and 
killing more people wherever it spreads.
PUBLIC HEALTH THREAT
■■ 250,000 infections per year requiring hospitalization or affecting already 
hospitalized patients.
■■ 14,000 deaths per year. 
■■ At least $1 billion in excess medical costs per year. 
■■ Deaths related to C. difficile increased 400% between 2000 and 2007, in part 
because of a stronger bacteria strain that emerged. 
■■ Almost half of infections occur in people younger than 65, but more than 
90% of deaths occur in people 65 and older. 
■■ About half of C. difficile infections first show symptoms in hospitalized or 
recently hospitalized patients, and half first show symptoms in nursing home 
patients or in people recently cared for in doctors’ offices and clinics.
CLOSTRIDIUM DIFFICILE
FIGHTING THE SPREAD OF RESISTANCE
Healthcare Providers Can:
■■ Prescribe antibiotics carefully (see http://www.cdc.gov/
getsmart/specific-groups/hcp/index.html). Once culture 
results are available, check whether the prescribed antibiotics 
are correct and necessary. 
■■ Order a C. difficile test (preferably a nucleic acid amplification test) 
WHAT CDC IS DOING
■■ Tracking and reporting national progress toward preventing  
C. difficile infections.
■■ Promoting C. difficile prevention programs and providing gold-
standard patient safety recommendations.
■■ Providing prevention expertise, as well as outbreak and laboratory 
assistance, to health departments and healthcare facilities.
WHAT YOU CAN DO
CEOs, Medical Officers, and other Healthcare 
Facility Leaders Can:
■■ Support better testing (nucleic acid amplification tests), 
tracking, and reporting of infections and prevention efforts.
■■ Ensure policies for rapid detection and isolation of patients 
with C. difficile are in place and followed.
■■ Assess hospital cleaning to be sure it is performed thoroughly,  
and augment this using an Environmental Protection Agency-
approved, spore-killing disinfectant in rooms where C. difficile 
patients are treated. 
■■ Notify other healthcare facilities about infectious diseases when 
patients transfer, especially between hospitals and nursing homes. 
■■ Participate in a regional C. difficile prevention effort. 
if the patient has had 3 or more unformed stools within 24 hours. 
■■ Be aware of infection rates in your facility or practice, and follow 
infection control recommendations with every patient. This includes 
using contact precautions (gloves and gowns) and isolation for 
patients who are suspected to have C. difficile, and continuing those 
practices for those with positive test results. 
Patients can:
■■ Take antibiotics only as prescribed by your doctor and  
complete the prescribed course of treatment. Antibiotics  
can be lifesaving medicines. 
■■ Tell your doctor if you have been on antibiotics and get diarrhea 
within a few months. 
■■ Wash your hands before eating and after using the bathroom. 
■■ Try to use a separate bathroom if you have diarrhea, or be sure the 
bathroom is cleaned well if someone with diarrhea has used it.
CS239559-B
ONLINE RESOURCES
Vital Signs, March 2012: Making Health Care Safer  
http://www.cdc.gov/vitalsigns/hai/




9,000 DRUG-RESISTANT INFECTIONSPER YEAR
CARBAPENEM- 
RESISTANT 
KLEBSIELLA SPP. 1,400 CARBAPENEM- RESISTANT E. COLI
600 DEATHS
CRE HAVE BECOME RESISTANT TO ALL  




This bacteria is an immediate public health threat  
that requires urgent and aggressive action.
Untreatable and hard-to-treat infections from carbapenem-resistant 
Enterobacteriaceae (CRE) bacteria are on the rise among patients in 
medical facilities. CRE have become resistant to all or nearly all the 
antibiotics we have today. Almost half of hospital patients who get 
bloodstream infections from CRE bacteria die from the infection.
RESISTANCE OF CONCERN
■■ Some Enterobacteriaceae are resistant to nearly all antibiotics, including carbapenems, 
which are often considered the antibiotics of last resort.
■■ More than 9,000 healthcare-associated infections are caused by CRE each year.
■■ CDC laboratories have confirmed at least one type of CRE in healthcare facilities in  
44 states.
■■ About 4% of U.S. short-stay hospitals had at least one patient with a serious CRE 
infection during the first half of 2012. About 18% of long-term acute care hospitals 
had one.
PUBLIC HEALTH THREAT
An estimated 140,000 healthcare-associated Enterobacteriaceae infections occur in the United 
States each year; about 9,300 of these are caused by CRE. Up to half of all bloodstream 
infections caused by CRE result in death. Fortunately, bloodstream infections account for 
a minority of all healthcare-associated infections caused by Enterobacteriaceae. Each year, 
approximately 600 deaths result from infections caused by the two most common types of 
CRE, carbapenem-resistant Klebsiella spp. and carbapenem-resistant E. coli. 
 



















FIGHTING THE SPREAD OF RESISTANCE
WHAT CDC IS DOING
■■ Tracking illness and identifying risk factors for CRE infections using two systems, 
the National Healthcare Safety Network and the Emerging Infections Program.
■■ Providing CRE outbreak support, such as staff expertise, prevention guidelines, 
tools, and lab assistance, to states and facilities. 
■■ Developing tests and prevention programs to identify and control CRE. 
CDC’s “Detect and Protect” effort (http://www.cdc.gov/hai/pdfs/cre/CDC_
DetectProtect.pdf) supports regional CRE programs. 
■■ Helping medical facilities improve antibiotic prescribing practices.
WHAT YOU CAN DO
States and Communities Can:
■■ Know CRE trends in your region. 
■■ Coordinate regional CRE tracking and control efforts in areas 
with CRE. Areas not yet or rarely affected by CRE infections can 
be proactive in CRE prevention efforts. 
■■ Require facilities to alert each other when transferring patients 
with any infection. 
■■ Consider including CRE infections on your state’s Notifiable Diseases list.
Healthcare CEOs, Medical Officers, and Other Healthcare Facility 
Leaders Can:
■■ Require and strictly enforce CDC guidance for CRE detection, prevention, 
tracking, and reporting. 
■■ Make sure your lab can accurately identify CRE and alert clinical and infection 
prevention staff when these bacteria are present. 
■■ Know CRE trends in your facility and in the facilities around you. 
■■ When transferring a patient, require staff to notify the other facility about 
infections, including CRE. 
■■ Join or start regional CRE prevention efforts, and promote wise antibiotic use. 
Health Care Providers Can:
■■ Know if patients with CRE are hospitalized at your facility, and 
stay aware of CRE infection risks. Ask if your patients have received 
medical care somewhere else, including another country. 
■■ Follow infection control recommendations with every patient, using 
contact precautions for patients with CRE. Whenever possible, dedicate 
rooms, equipment, and staff to CRE patients. 
■■ Prescribe antibiotics wisely (http://www.cdc.gov/getsmart/healthcare). Use 
culture results to modify prescriptions if needed. 
■■ Remove temporary medical devices as soon as possible. 
Patients Can:
■■ Tell your doctor if you have been hospitalized in another  
facility or country. 
■■ Take antibiotics only as prescribed. 
■■ Insist that everyone wash their hands before touching you.
ONLINE RESOURCES
Vital Signs, March 2013: Making Health Care Safer  
 
2012 CRE Toolkit 
http://www.cdc.gov/hai/organisms/cre/cre-toolkit/index.html
MMWR, March 2013 
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6209a3.htm?s_cid=mm6209a3_w
Get Smart for Healthcare 
http://www.cdc.gov/getsmart/healthcare

















820,000 GONOCOCCAL INFECTIONS  PER YEAR
THREAT LEVEL
URGENT
This bacteria is an immediate public health threat  
that requires urgent and aggressive action.
Neisseria gonorrhoeae causes gonorrhea, a sexually transmitted 
disease that can result in discharge and inflammation at the 
urethra, cervix, pharynx, or rectum.
RESISTANCE OF CONCERN
N. gonorrhoeae is showing resistance to antibiotics usually used to treat it. These  
drugs include:
■■ cefixime (an oral cephalosporin)




Gonorrhea is the second most commonly reported notifiable infection in the United 
States and is easily transmitted. It causes severe reproductive complications and 
disproportionately affects sexual, racial, and ethnic minorities. Gonorrhea control relies on 
prompt identification and treatment of infected persons and their sex partners. Because 
some drugs are less effective in treating gonorrhea, CDC recently updated its treatment 
guidelines to slow the emergence of drug resistance. CDC now recommends only ceftriaxone 
plus either azithromycin or doxycycline as first-line treatment for gonorrhea. The emergence 
of cephalosporin resistance, especially ceftriaxone resistance, would greatly limit treatment 
options and could cripple gonorrhea control efforts. 
In 2011, 321,849 cases of gonorrhea were reported to CDC, but CDC estimates that more 
than 800,000 cases occur annually in the United States.
  Percentage Estimated number of cases
Gonorrhea 820,000
Resistance to any antibiotic 30% 246,000
Reduced susceptibility to cefixime <1% 11,480
Reduced susceptibility to ceftriaxone <1% 3,280
Reduced susceptibility to azithromycin <1% 2,460
Resistance to tetracycline 23% 188,600
Source: The Gonococcal Isolate Surveillance Project (GISP)–5,900 isolates tested for susceptibility in 2011.




FIGHTING THE SPREAD OF RESISTANCE
Cephalosporin-resistant N. gonorrhoeae is often resistant to multiple classes of other antibiotics 
and as a result, infections caused by these bacteria will likely fail empiric treatment regimens. If 
cephalosporin-resistant N. gonorrhoeae becomes widespread, the public health impact during a 
10-year period is estimated to be 75,000 additional cases of pelvic inflammatory disease (a major 
cause of infertility), 15,000 cases of epididymitis, and 222 additional HIV infections because HIV is 
transmitted more readily when someone is co-infected with gonorrhea. In addition, the estimated 
direct medical costs would total $235 million. Additional costs are anticipated to be incurred as a 
result of increased susceptibility monitoring, provider education, case management, and the need 
for additional courses of antibiotics and follow-up. 
Gonorrhea is a global problem, requiring a global approach. Action in the United States alone 
is unlikely to prevent resistance from developing, but rapid detection and effective treatment 
of patients and their partners might slow the spread of resistance. Preventing gonorrhea is 
critical. Screening, rapid detection, prompt treatment, and partner services are the foundations of 
gonorrhea control in the United States. Effectively addressing the heavy burden of gonorrhea and 
anticipated arrival of cephalosporin resistance requires continued use of these strategies as well 
as the use of expedited partner therapy, promotion of safer sexual behaviors such as abstinence, 
mutual monogamy, and correct and consistent condom use, and activities designed to rapidly 
detect and respond to antibiotic-resistant infections
WHAT CDC IS DOING
CDC is closely monitoring resistance in N. gonorrhoeae in the United States and actively 
collaborating with the World Health Organization to enhance global surveillance. In the 
United States, CDC recently released a national response plan and is working closely with 
local and state STD programs to enhance preparedness. CDC recently updated its gonorrhea 
treatment recommendations to stay a step ahead of this rapidly evolving bacterium, and is 








such as penicillin, 
remains common.
Prevalence of Penicillin, Tetracycline and Fluoroquinolone  
Resistance and Reduced Cefixime Susceptibility in  
N. gonorrhoeae isolates, U.S., 1987-2011
Source: The Gonococcal Isolate Surveillance Project (GISP).
These trends are 
an early warning 
of cephalosporin 
resistance.
Prevalence of N. gonorrhoeae isolates with reduced cefixime  
(MICs ≥ 0.25μg/ml) and ceftriaxone (MICs ≥ 0.125μg/ml) 
susceptibility, U.S. 2006–2011




CDC’s gonorrhea website 
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MICROORGANISMS WITH  
A THREAT LEVEL OF SERIOUS
Multidrug-resistant Acinetobacter
Drug-resistant Campylobacter
Fluconazole-resistant Candida (a fungus)











These bacteria are a serious 
concern and require prompt and 
sustained action to ensure the 









12,000 ACINETOBACTER INFECTIONSPER YEAR
AT LEAST THREE DIFFERENT CLASSES OF ANTIBIOTICS  




This bacteria is a serious concern and requires prompt  
and sustained action to ensure the problem does not grow.
Acinetobacter is a type of gram-negative bacteria that is a 
cause of pneumonia or bloodstream infections among critically 
ill patients. Many of these bacteria have become very resistant 
to antibiotics. 
RESISTANCE OF CONCERN
Some Acinetobacter strains are resistant to nearly all or all antibiotics including 
carbapenems, often considered antibiotics of last resort.
■■ About 63% of Acinetobacter is considered multidrug-resistant, 
meaning at least three different classes of antibiotics no longer cure 
Acinetobacter infections.
■■ Approximately 2% of healthcare-associated infections reported to CDC’s 
National Healthcare Safety Network are caused by Acinetobacter, but 
the proportion is higher among critically ill patients on mechanical 
ventilators (about 7%). 
PUBLIC HEALTH THREAT
An estimated 12,000 healthcare-associated Acinetobacter infections occur in 
the United States each year. Nearly 7,000 (or 63%) of these are multidrug-
resistant, and about 500 deaths are attributed to these infections.
Percentage of all Acinetobacter 
healthcare-associated 












For more information about data methods and references, please see technical appendix.
MULTIDRUG-RESISTANT 
ACINETOBACTER
FIGHTING THE SPREAD OF RESISTANCE
WHAT CDC IS DOING
■■ Tracking illness and identifying risk factors for drug-resistant infections 
using two systems, the National Healthcare Safety Network and the 
Emerging Infections Program.
■■ Providing outbreak support such as staff expertise, prevention guidelines, 
tools, and lab assistance, to states and facilities. 
■■ Developing tests and prevention recommendations to control drug-
resistant infections.
■■ Helping medical facilities improve antibiotic prescribing practices.
WHAT YOU CAN DO
States and Communities Can:
■■ Know resistance trends in your region. 
■■ Coordinate local and regional infection tracking and 
control efforts. 
■■ Require facilities to alert each other when transferring patients with  
any infection.
Healthcare CEOs, Medical Officers, and other Healthcare 
Facility Leaders Can:
■■ Require and strictly enforce CDC guidance for infection detection, 
prevention, tracking, and reporting. 
■■ Make sure your lab can accurately identify infections and alert clinical and 
infection prevention staff when these bacteria are present. 
■■ Know infection and resistance trends in your facility and in the facilities 
around you. 
■■ When transferring a patient, require staff to notify the other facility about 
all infections. 
■■ Join or start regional infection prevention efforts.
■■ Promote wise antibiotic use.
Healthcare Providers Can:
■■ Know the type of drug-resistant infections that are present in your 
facility and patients.
■● Request immediate alerts when the lab identifies drug-resistant 
infections in your patients.
■● Alert the other facility when you transfer a patient with a drug-
resistant infection. 
■■ Protect patients from drug-resistant infections.
■● Follow relevant guidelines and precautions at every patient encounter.
■● Prescribe antibiotics wisely.
■● Remove temporary medical devices such as catheters and ventilators as 
soon as no longer needed. 
Patients and Their Loved Ones Can:
■■ Ask everyone including doctors, nurses, other medical staff,  
and visitors, to wash their hands before touching the patient.
■■ Take antibiotics exactly as prescribed.
CS239559-B
ONLINE RESOURCES
Acinetobacter in Healthcare Settings 
http://www.cdc.gov/HAI/organisms/acinetobacter.html


















This bacteria is a serious concern and requires prompt  
and sustained action to ensure the problem does not grow.
Campylobacter usually causes diarrhea (often bloody), 
fever, and abdominal cramps, and sometimes causes 
serious complications such as temporary paralysis.
RESISTANCE OF CONCERN
Physicians rely on drugs like ciprofloxacin and azithromycin for treating 
patients with severe disease. Resistant infections sometimes last longer. 




Campylobacter is estimated to cause approximately 1.3 million 
infections, 13,000 hospitalizations, and 120 deaths each year in the 
United States. CDC is seeing resistance to ciprofloxacin in almost 25%  
of Campylobacter tested and resistance to azithromycin in about 
2%. Costs are expected to be higher for resistant infections because 
antibiotic-resistant Campylobacter infections sometimes last longer. 
Percentage of all 
Campylobacter*
Estimated number 
of illnesses per year
Estimated illnesses 





Resistance to ciprofloxacin 23% 310,000 102.3 28
Resistance to azithromycin 2% 22,000 7.4 <5
Resistance to azithromycin 
or ciprofloxacin 24% 310,000 103.9 28
Campylobacter drug 
resistance increased 
from 13% in 1997 to 







*Data for 1989–1990 were from a sentinel 
county survey. Annual testing began in 1997.
For more information about data methods and 
references, please see appendix.
DRUG-RESISTANT 
CAMPYLOBACTER
FIGHTING THE SPREAD OF RESISTANCE
Campylobacter spreads from animals to people through contaminated food, 
particularly raw or undercooked chicken and unpasteurized milk. Infections 
may also be acquired through contact with animals and by drinking 
contaminated water. Antibiotic use in food animals can result in resistant 
Campylobacter that can spread to humans. Resistant Campylobacter are 
common in many countries and cause illness in travelers. Key measures to 
prevent resistant infections include:
■■ Avoiding inappropriate antibiotic use in food animals.
■■ Tracking antibiotic use in different types of food animals.
■■ Stopping spread of Campylobacter among animals on farms.
■■ Improving food production and processing to reduce contamination. 
■■ Educating consumers and food workers about safe food handling 
practices.
WHAT CDC IS DOING
■■ Tracking changes in antibiotic resistance through ongoing 
surveillance. 
■■ Promoting initiatives that measure and improve antibiotic use in 
food animals. 
■■ Determining foods responsible for outbreaks of Campylobacter 
infections.
■■ Supporting and improving local, state, and federal public  
health surveillance. 
■■ Guiding prevention efforts by estimating how much illness occurs 
and identifying the sources of infection.
■■ Educating people about how to avoid Campylobacter infections.
WHAT YOU CAN DO
■■ Clean. Wash hands, cutting boards, utensils, sinks, 
and countertops.
■■ Separate. Keep raw meat, poultry, and seafood 
separate from ready-to-eat foods.
■■ Cook. Use a food thermometer to ensure that foods are cooked to a 
safe internal temperature.
■■ Chill. Keep your refrigerator below 40°F and refrigerate food that 
will spoil.
■■ Avoid drinking raw milk and untreated water.
■■ Report suspected illness from food to your local health department.
■■ Don’t prepare food for others if you have diarrhea or vomiting.
■■ Be especially careful preparing food for children, pregnant women, 
those in poor health, and older adults.
■■ Consume safe food and water when traveling abroad.
ONLINE RESOURCES
National Antimicrobial Resistance Monitoring System 
http://www.cdc.gov/narms




















This fungus is a serious concern and requires prompt  
and sustained action to ensure the problem does not grow.
Candidiasis is a fungal infection caused by yeasts of the genus Candida. 
There are more than 20 species of Candida yeasts that can cause infection 
in humans, the most common of which is Candida albicans. Candida yeasts 
normally live on the skin and mucous membranes without causing infection. 
However, overgrowth of these microorganisms can cause symptoms to 
develop. Symptoms of candidiasis vary depending on the area of the body 
that is infected. 
Candida is the fourth most common cause of healthcare-associated 
bloodstream infections in the United States. In some hospitals it is the most 
common cause. These infections tend to occur in the sickest of patients.
RESISTANCE OF CONCERN
■■ Some Candida strains are increasingly resistant to first-line and second-line antifungal 
treatment agents. Recent data demonstrate a marked shift among infections towards 
Candida species with increased resistance to antifungal drugs including azoles and  
echinocandins. 
■■ CDC conducts multicenter surveillance for antifungal resistance in the United States, 
candidal infections, their economic impact, and possible areas where prevention and 
control strategies can be focused.
PUBLIC HEALTH THREAT
An estimated 46,000 healthcare-associated Candida infections occur among hospitalized 
patients in the United States each year. Roughly 30% of patients with bloodstream 
infections (candidemia) with drug-resistant Candida die during their hospitalization. 
CDC estimates that each case of Candida infection results in 3–13 days of additional 
hospitalization, and a total of $6,000–$29,000 in direct healthcare costs. Based on these 
estimates, we calculate resistant Candida infections may add millions of dollars in excess 
costs to U.S. healthcare expenditures each year.
 
Percentage of Candida 
bloodstream isolates 
testing resistant 







For more information about data methods and references, please see technical appendix.
FLUCONAZOLE-RESISTANT
CANDIDA
FIGHTING THE SPREAD OF RESISTANCE
Prevention strategies for candidemia are not well defined. Most infectious are thought to be caused by Candida that the patient carries on his or her own body. Therapy to 
prevent infections (antifungal prophylaxis) may be appropriate for some groups at high risk of developing Candida bloodstream infection, such as low-birth-weight infants.  
CDC recommendations for catheter care and handwashing can be helpful in reducing transmission in healthcare institutions. 
WHAT CDC IS DOING
Prevention of significant morbidity and mortality from candidemia remains a challenge. Although antifungal prophylaxis has been shown to be effective in selected 
patient populations, there is still debate on the application of risk prevention tools and other prevention strategies. There is a continued need for surveillance of 
candidemia to develop and evaluate prevention strategies and to monitor for changes in incidence and resistance.
There is increasing 
incidence of Candida 
infections due to azole- 
and echinocandin-
resistant strains.
Changes Over Time in Incidence of Resistant Species of Candida
CS239559-B
*This accounts for data collected from Atlanta, GA from 1992-1993 and from Baltimore, MD from 1998–2000.
**This accounts for data collected from 2008–present. 
ONLINE RESOURCES

















This bacteria is a serious concern and requires prompt  
and sustained action to ensure the problem does not grow.
Extended-spectrum β-lactamase is an enzyme that allows bacteria to 
become resistant to a wide variety of penicillins and cephalosporins. 
Bacteria that contain this enzyme are known as ESBLs or ESBL-
producing bacteria. ESBL-producing Enterobacteriaceae are resistant to 
strong antibiotics including extended spectrum cephalosporins.
RESISTANCE OF CONCERN
Some Enterobacteriaceae are resistant to nearly all:
■■ penicillins
■■ cephalosporins
In these cases, the remaining treatment option is an antibiotic from the carbapenem  
family. These are drugs of last resort, and use of them is also contributing to resistance (see 
CRE fact sheet).
■■ Nearly 26,000 (or 19%) healthcare-associated Enterobacteriaceae infections are 
caused by ESBL-producing Enterobacteriaceae.
■■ Patients with bloodstream infections caused by ESBL-producing Enterobacteriaceae 
are about 57% more likely to die than those with bloodstream infections caused by 
a non ESBL-producing strain.
PUBLIC HEALTH THREAT
An estimated 140,000 healthcare-associated Enterobacteriaceae infections occur in the 
United States each year. CDC estimates that bloodstream infections caused by ESBL-
containing Enterobacteriaceae result in upwards of $40,000 in excess hospital charges per 
occurrence. Approximately 26,000 infections and 1,700 deaths are attributable to ESBLs.
 
Percentage of Enterobacteriaceae 
healthcare-associated infections resistant 










ESBL-producing E. coli 14% 9,000 600
Totals   26,000 1,700
For more information about data methods and references, please see technical appendix.
EXTENDED SPECTRUM β-LACTAMASE (ESBL) PRODUCING
ENTEROBACTERIACEAE
WHAT CDC IS DOING
■■ Tracking illness and identifying risk factors for drug-resistant 
infections using two systems, the National Healthcare Safety Network 
and the Emerging Infections Program.
■■ Providing outbreak support, such as staff expertise, prevention 
guidelines, tools, and lab assistance, to states and facilities. 
■■ Developing tests and prevention recommendations to control drug-
resistant infections.
■■ Helping medical facilities improve antibiotic prescribing practices.
WHAT YOU CAN DO
States and Communities Can:
■■ Know resistance trends in your region. 
■■ Coordinate local and regional infection tracking and 
control efforts. 
■■ Require facilities to alert each other when transferring 
patients with any infection.
Health Care CEOs, Medical Officers, and Other Healthcare 
Facility Leaders Can:
■■ Require and strictly enforce CDC guidance for infection detection, 
prevention, tracking, and reporting. 
■■ Make sure your lab can accurately identify infections and alert clinical 
and infection prevention staff when these bacteria are present. 
■■ Know infection and resistance trends in your facility and in the 
facilities around you. 
■■ When transferring a patient, require staff to notify the other facility 
about all infections. 
■■ Join or start regional infection prevention efforts.
■■ Promote wise antibiotic use.
FIGHTING THE SPREAD OF RESISTANCE
Healthcare Providers Can:
■■ Know when and what types of drug-resistant infections are 
present in your facility and patients.
■■ Request immediate alerts when the lab identifies drug-resistant 
infections in your patients.
■■ Alert the other facility when you transfer a patient with a drug-
resistant infection. 
■■ Protect patients from drug-resistant infections.
■■ Follow relevant guidelines and precautions at every patient encounter.
■■ Prescribe antibiotics wisely.
■■ Remove temporary medical devices such as catheters and ventilators 
as soon as no longer needed.
Patients and Their Loved Ones Can:
■■ Ask everyone including doctors, nurses, other medical  
staff, and visitors, to wash their hands before touching  
the patient.
■■ Take antibiotics only and exactly as prescribed.
CS239559-B
ONLINE RESOURCES
CDC’s Heathcare-associated Infections(HAI) website 
www.cdc.gov/hai 





Enterococci cause a range of illnesses, mostly among patients receiving healthcare, but include bloodstream infections, surgical site 
infections, and urinary tract infections.
RESISTANCE OF CONCERN
■■ Enterococcus often cause infections among very sick patients in hospitals 
and other healthcare-settings.
■■ Some Enterococcus strains are resistant to vancomycin, an antibiotic of last 
resort, leaving few or no treatment options.
■■ About 20,000 (or 30%) of Enterococcus healthcare-associated infections are 
vancomycin resistant.
PUBLIC HEALTH THREAT
An estimated 66,000 healthcare-associated Enterococcus infections occur in the 
United States each year. The proportion of infections that occur with a vancomycin 
resistant strain differs by the species of Enterococcus; overall 20,000 vancomycin-
resistant infections occurred among hospitalized patients each year, with 
approximately 1,300 deaths attributed to these infections.
 


















Totals   20,000 1,300
For more information about data methods and references, please see technical appendix.
20,000 1,300






This bacteria is a serious concern and requires prompt  
and sustained action to ensure the problem does not grow.
SOME ENTEROCOCCUS STRAINS ARE RESISTANT TO VANCOMYCIN  
LEAVING FEW OR NO TREATMENT OPTIONS
66,000 ENTEROCOCCUS INFECTIONSPER YEAR
VANCOMYCIN-RESISTANT 
ENTEROCOCCUS (VRE)
WHAT CDC IS DOING
■■ Tracking illness and identifying risk factors for drug-resistant 
infections using two systems, the National Healthcare Safety Network 
and the Emerging Infections Program.
■■ Providing outbreak support such as staff expertise, prevention 
guidelines, tools, and lab assistance, to states and facilities. 
■■ Developing tests and prevention recommendations to control drug-
resistant infections.
■■ Helping medical facilities improve antibiotic prescribing practices.
WHAT YOU CAN DO
States and Communities can:
■■ Know resistance trends in your region. 
■■ Coordinate local and regional infection tracking and 
control efforts. 
■■ Require facilities to alert each other when transferring patients with 
any infection.
Healthcare CEOs, Medical Officers, and other Healthcare 
Facility Leaders can:
■■ Require and strictly enforce CDC guidance for infection detection, 
prevention, tracking, and reporting. 
■■ Make sure your lab can accurately identify infections and alert clinical 
and infection prevention staff when these germs are present. 
■■ Know infection and resistance trends in your facility and in the 
facilities around you. 
■■ When transferring a patient, require staff to notify the other facility 
about all infections. 
■■ Join or start regional infection prevention efforts.
■■ Promote wise antibiotic use.
FIGHTING THE SPREAD OF RESISTANCE
Doctors and Nurses can:
■■ Know when and what types of drug-resistant infections are 
present in your facility and patients Request immediate 
alerts when the lab identifies drug-resistant infections in 
your patients.
■■ Alert the other facility when you transfer a patient with a drug-
resistant infection. 
■■ Protect patients from drug-resistant infections.
■■ Follow relevant guidelines and precautions at every patient encounter.
■■ Prescribe antibiotics wisely.
■■ Remove temporary medical devices such as catheters and ventilators 
as soon as no longer needed.
Patients and their loved ones can:
■■ Ask everyone including doctors, nurses, other medical staff, and 
visitors, to wash their hands before touching the patient.
■■ Take antibiotics only and exactly as prescribed.
CS239559-B
ONLINE RESOURCES
Vancomycin-resistant Enterococci (VRE) in 
Healthcare Settings 
http://www.cdc.gov/HAI/organisms/vre/vre.html 
Healthcare-associated Infections (HAIs), 




Pseudomonas aeruginosa is a common cause of healthcare-associated infections including pneumonia, bloodstream infections, urinary 
tract infections, and surgical site infections.
RESISTANCE OF CONCERN
■■ Some strains of Pseudomonas aeruginosa have been found to be resistant 
to nearly all or all antibiotics including aminoglycosides, cephalosporins, 
fluoroquinolones, and carbapenems. 
■■ Approximately 8% of all healthcare-associated infections reported to CDC’s 
National Healthcare Safety Network are caused by Pseudomonas aeruginosa. 
■■ About 13% of severe healthcare-associated infections caused by 
Pseudomonas aeruginosa are multidrug resistant, meaning several classes of 
antibiotics no longer cure these infections.
PUBLIC HEALTH THREAT
An estimated 51,000 healthcare-associated Pseudomonas aeruginosa infections 
occur in the United States each year. More than 6,000 (or 13%) of these are 
multidrug-resistant, with roughly 400 deaths per year attributed to these 
infections. 
 
Percentage of all Pseudomonas 
aeruginosa healthcare-










Pseudomonas aeruginosa 13% 6,700 440








This bacteria is a serious concern and requires prompt  
and sustained action to ensure the problem does not grow.
51,000 PSEUDOMONAS INFECTIONS PER YEAR
MULTIDRUG-RESISTANT
PSEUDOMONAS AERUGINOSA
WHAT CDC IS DOING
■■ Identifying and tracking risk factors for drug-resistant infections using 
two systems, the National Healthcare Safety Network and the Emerging 
Infections Program.
■■ Providing outbreak support such as staff expertise, prevention 
guidelines, tools, and lab assistance, to states and facilities. 
■■ Developing tests and prevention recommendations to control drug-
resistant infections.
■■ Helping medical facilities improve antibiotic prescribing practices.
WHAT YOU CAN DO
States and Communities Can:
■■ Know resistance trends in your region. 
■■ Coordinate local and regional infection tracking and 
control efforts. 
■■ Require facilities to alert each other when transferring 
patients with any infection. 
Health Care CEOs, Medical Officers, and Other Healthcare 
Facility Leaders Can:
■■ Require and strictly enforce CDC guidance for infection detection, 
prevention, tracking, and reporting. 
■■ Make sure your lab can accurately identify infections and alert clinical 
and infection prevention staff when these bacteria are present. 
■■ Know infection and resistance trends in your facility and in the 
facilities around you. 
■■ When transferring a patient, require staff to notify the other facility 
about all infections. 
■■ Join or start regional infection prevention efforts.
■■ Promote wise antibiotic use.
FIGHTING THE SPREAD OF RESISTANCE
Healthcare Providers Can:
■■ Know when and what types of drug-resistant infections that 
are present in your facility and patients.
■■ Request immediate alerts when the lab identifies drug-
resistant infections in your patients.
■■ Alert the other facility when you transfer a patient with a drug-
resistant infection. 
■■ Protect patients from drug-resistant infections.
■■ Follow relevant guidelines and precautions at every patient encounter.
■■ Prescribe antibiotics wisely.
■■ Remove temporary medical devices such as catheters and ventilators 
as soon as no longer needed.
Patients and Their Loved Ones Can:
■■ Ask everyone including doctors, nurses, other medical  
staff, and visitors, to wash their hands before touching  
the patient.
■■ Take antibiotics only and exactly as prescribed.
CS239559-B
ONLINE RESOURCES
Healthcare-associated Infections (HAI) 
www.cdc.gov/hai  










SALMONELLA INFECTIONS PER YEAR
$365,000,000
IN MEDICAL COSTS PER YEAR
THREAT LEVEL
SERIOUS
This bacteria is a serious concern and requires prompt  
and sustained action to ensure the problem does not grow.
Non-typhoidal Salmonella (serotypes other than Typhi, Paratyphi A, Paratyphi B, and Paratyphi C) usually causes diarrhea (sometimes 
bloody), fever, and abdominal cramps. Some infections spread to the blood and can have life-threatening complications.
RESISTANCE OF CONCERN
Physicians rely on drugs, such as ceftriaxone and ciprofloxacin, for treating patients with 
complicated Salmonella infections. Resistant infections are more severe and have higher 
hospitalization rates. Non-typhoidal Salmonella is showing resistance to:
■■ ceftriaxone
■■ ciprofloxacin 
■■ multiple classes of drugs
PUBLIC HEALTH THREAT
Non-typhoidal Salmonella causes approximately 1.2 million illnesses, 23,000 
hospitalizations, and 450 deaths each year in the United States. Direct medical costs are 
estimated to be $365 million annually. CDC is seeing resistance to ceftriaxone in about 
3% of non-typhoidal Salmonella tested, and some level of resistance to ciprofloxacin in 
about 3%. About 5% of non-typhoidal Salmonella tested by CDC are resistant to five or 
more types of drugs. Costs are expected to be higher for resistant than for susceptible 
infections because resistant infections are more severe, those patients are more likely to be 


















Ceftriaxone resistance 3% 36,000 12.0 13
Ciprofloxacin resistance or 
partial resistance
3% 33,000 10.9 12
Resistance to 5 or more 
antibiotic classes 
5% 66,000 21.9 24
Any resistance pattern above 8% 100,000 34.1 38
*3-year average (2009–2011)
For more information about data methods and references, please see technical appendix.
DRUG-RESISTANT NON-TYPHOIDAL
SALMONELLA
FIGHTING THE SPREAD OF RESISTANCE
Salmonella spreads from animals to people mostly through food. Antibiotic use 
in food animals can result in resistant Salmonella, and people get sick when 
they eat foods contaminated with Salmonella. Key measures to prevent resistant 
infections include:
■■ Avoiding inappropriate antibiotic use in food animals.
■■ Tracking antibiotic use in different types of food animals. 
■■ Stopping spread of Salmonella among animals on farms.
■■ Improving food production and processing to reduce contamination. 
■■ Educating consumers and food workers about safe food handling 
practices.
WHAT CDC IS DOING
■■ Tracking changes in antibiotic resistance through ongoing surveillance. 
■■ Promoting initiatives that measure and improve antibiotic use in  
food animals. 
■■ Determining foods responsible for outbreaks of Salmonella infections.
■■ Supporting and improving local, state, and federal public health 
surveillance. 
■■ Guiding prevention efforts by estimating how much illness occurs and 
identifying the sources of infection.
■■ Educating people about how to avoid Salmonella infections.
WHAT YOU CAN DO
■■ Clean. Wash hands, cutting boards, utensils, and  
countertops.
■■ Separate. Keep raw meat, poultry, and seafood  
separate from ready-to-eat foods.
■■ Cook. Use a food thermometer to ensure that foods are cooked to a  
safe internal temperature.
■■ Chill. Keep your refrigerator below 40°F and refrigerate food that  
will spoil.
■■ Avoid drinking raw milk.
■■ Report suspected illness from food to your local health department.
■■ Don’t prepare food for others if you have diarrhea or vomiting.
■■ Be especially careful preparing food for children, pregnant women, those 







Resistance in Non-Typhoidal Salmonella, 1996–2011
For more information about data methods and references, please see appendix.
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TYPHI INFECTIONS PER YEAR 
IN THE U.S.
67%





DUE TO SALMONELLA TYPHI 
PER YEAR IN THE U.S.
21,700,000 SALMONELLA TYPHI INFECTIONS WORLDWIDE
THREAT LEVEL
SERIOUS
This bacteria is a serious concern and requires prompt  
and sustained action to ensure the problem does not grow.
Salmonella serotype Typhi causes typhoid fever, a potentially life-threatening disease. People with typhoid fever usually have a high 
fever, abdominal pain, and headache. Typhoid fever can lead to bowel perforation, shock, and death.
RESISTANCE OF CONCERN
Physicians rely on drugs such as ceftriaxone, azithromycin, and ciprofloxacin for treating 
patients with typhoid fever. Salmonella serotype Typhi is showing resistance to: 
■■ ceftriaxone
■■ azithromycin
■■ ciprofloxacin (resistance is so common that it cannot be routinely used)
PUBLIC HEALTH THREAT
Salmonella Typhi causes approximately 21.7 million illnesses worldwide. In the United 
States, it causes approximately 5,700 illnesses and 620 hospitalizations each year. Most 
illnesses occur in people who travel to some parts of the developing world where the 
disease is common. Travel-associated infections are more likely to be antibiotic resistant. 
CDC is seeing some level of resistance to ciprofloxacin in two-thirds of Salmonella Typhi 
tested. CDC has not yet seen resistance to ceftriaxone or azithromycin in the United States, 
but this has been seen in other parts of the world. Resistant infections are likely to cost 
more than susceptible infections because illness may last longer. Deaths in the United 

















partial resistance to 
ciprofloxacin
67% 3,800 1.3 <5
*3-year average (2009–2011)
For more information about data methods and references, please see technical appendix.
DRUG-RESISTANT
SALMONELLA SEROTYPE TYPHI
FIGHTING THE SPREAD OF RESISTANCE
Salmonella serotype Typhi spreads from one person to another through food or water 
contaminated with feces. Typhoid fever is common in developing countries lacking 
safe water and adequate sanitation. Most U.S. cases are associated with travel to those 
countries. Sometimes the source is a carrier who is no longer ill, but is still infected. Key 
measures to prevent the spread of resistant infections include:
■■ Vaccinating people traveling to countries where typhoid fever is common.
■■ Consuming safe food and water when traveling in those countries. 
■■ Improving access to clean water and sanitation for people living in those 
countries. 
■■ Reporting changes in resistance to people who diagnose and treat patients with 
typhoid fever.
■■ Investigating cases of typhoid fever to identify and treat carriers.
WHAT CDC IS DOING
■■ Providing recommendations for travelers on vaccination, safe food, and clean 
water.
■■ Tracking and reporting changes in antibiotic resistance through ongoing 
surveillance.
■■ Determining settings and high-risk groups for resistant infections in the U.S. and 
other countries.
■■ Educating healthcare providers about specific resistance problems and the need to 
vaccinate travelers.
■■ Promoting safer water and sanitation in countries where typhoid fever is common.
■■ Building public health capacity in other countries to diagnose, track, and control 
typhoid fever.
WHAT YOU CAN DO
If you’re traveling to a country where typhoid fever is common: 
■■ Get vaccinated against typhoid fever before you depart.
■■ Choose foods and drinks carefully while traveling even if you are  
vaccinated. That means: boil it, cook it, peel it, or forget it.
■● Boil or treat water yourself.
■● Eat foods that are hot and steaming.
■● Avoid raw fruits and vegetables unless you peel them yourself.
■● Avoid cold food and beverages from street vendors.
■■ If you get sick with high fever and a headache during or after travel, seek medical 
care at once and tell the healthcare provider where you have traveled. 
ONLINE RESOURCES







Typhi has jumped 
significantly—
from about 20% in 
1999 to more than 
70% in 2011.
Increasing Resistance or Partial Resistance to Ciprofloxacin  
in Salmonella Typhi, 1999-2011*





27,000 DRUG-RESISTANT SHIGELLA INFECTIONS PER YEAR
500,000 SHIGELLA INFECTIONS PER YEAR 40 DEATHS PER YEAR
THREAT LEVEL
SERIOUS
This bacteria is a serious concern and requires prompt  
and sustained action to ensure the problem does not grow.
Shigella usually causes diarrhea (sometimes bloody), fever, and abdominal pain. Sometimes it causes serious complications such as reactive 
arthritis. High-risk groups include young children, people with inadequate handwashing and hygiene habits, and men who have sex with men.
RESISTANCE OF CONCERN
Resistance to traditional first-line drugs such as ampicillin and trimethoprim-
sulfamethoxazole has become so high that physicians must now rely on alternative 
drugs like ciprofloxacin and azithromycin to treat infections. Resistant infections 
can last longer than infections with susceptible bacteria (bacteria that can be 




Shigella causes approximately 500,000 diarrheal illnesses, 5,500 hospitalizations, 
and 40 deaths each year in the United States. CDC is seeing resistance to 
ciprofloxacin in 1.6% of the Shigella cases tested and resistance to azithromycin 
in approximately 3%. Because initial treatment can fail, costs are expected to be 
















Ciprofloxacin resistance 2% 12,000 4.0 <5
Azithromycin resistance 3% 15,000 5.1 <5
Azithromycin or 
ciprofloxacin resistance
6% 27,000 9.1 <5
*Percentage of all isolates that were resistant in 2011.
For more information about data methods and references, please see technical appendix.
DRUG-RESISTANT
SHIGELLA
FIGHTING THE SPREAD OF RESISTANCE
Shigella spreads from one person to another in feces through direct 
contact, or through contaminated surfaces, food, or water. Antibiotic use 
in humans can result in resistant Shigella and hasten further spread. Key 
measures to prevent resistant infections include:
■■ Promoting thorough and frequent hand washing with soap, 
especially in child care centers, elementary schools, restaurants, 
and homes with small children.
■■ Using antibiotics to treat more severe Shigella infections and 
managing milder infections with fluids and rest.
■■ Reporting changes in resistance to healthcare providers. 
■■ Detecting and controlling outbreaks of Shigella infections.
■■ Educating consumers and food workers about safe food handling 
practices.
WHAT CDC IS DOING
■■ Tracking changes in antibiotic resistance through ongoing 
surveillance.
■■ Determining settings and high-risk groups for outbreaks of 
resistant infections.
■■ Educating healthcare providers about specific resistance problems.
■■ Promoting prudent antibiotic use and handwashing.
WHAT YOU CAN DO
■■ Don’t prepare food for others if you have diarrhea  
or vomiting.
■■ Keep children who have diarrhea and who are in  
diapers out of child care settings and swimming pools.
■■ Avoid sexual behavior that is likely to transmit infection when you 
have diarrhea.















Resistance to Ampicillin and Trimethoprim-Sulfamethoxazole  
in Shigella, 1978–2011*
*Data for 1978-1995 were from three sentinel county surveys. Annual testing  began in 1999.
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This bacteria is a serious concern and requires prompt  
and sustained action to ensure the problem does not grow.
Methicillin-resistant Staphylococcus aureus (MRSA) causes a range 
of illnesses, from skin and wound infections to pneumonia and 
bloodstream infections that can cause sepsis and death. Staph 
bacteria, including MRSA, are one of the most common causes of 
healthcare-associated infections.
RESISTANCE OF CONCERN
Resistance to methicillin and related antibiotics (e.g., nafcillin, oxacillin) and 
resistance to cephalosporins are of concern.
PUBLIC HEALTH THREAT 
CDC estimates 80,461 invasive MRSA infections and 11,285 related deaths occurred in 
2011. An unknown but much higher number of less severe infections occurred in both 




during or soon 
after inpatient 
medical care.
Revised Annualized National Estimates,  
ABCs MRSA 2005–2011 (updated Nov, 2012)
For more information about data methods and references, please see technical appendix.
METHICILLIN-RESISTANT
STAPHYLOCOCCUS AUREUS (MRSA)
FIGHTING THE SPREAD OF RESISTANCE
Although still a common and severe threat to patients, invasive MRSA infections in healthcare settings appear to be declining. Between 2005 and 2011 overall rates of invasive 
MRSA dropped 31%; the largest declines (54%) were observed among infections occurring during hospitalization. Success began with preventing central-line associated 
bloodstream infections with MRSA, where rates fell nearly 50% from 1997 to 2007. 
During the past decade, rates of MRSA infections have increased rapidly among the general population (people who have not recently received care in a healthcare setting). 
There is some evidence that these increases are slowing, but they are not following the same downward trends as healthcare-associated MRSA.
WHAT CDC IS DOING
■■ Tracking illness and identifying risk factors for drug-resistant infections using  
two systems, the National Healthcare Safety Network and the Emerging  
Infections Program.
■■ Providing states and facilities with outbreak support such as staff expertise, 
prevention guidelines, tools, and lab assistance. 
■■ Developing tests and prevention recommendations to control drug-resistant 
infections.
■■ Helping healthcare facilities improve antibiotic prescribing practices.
WHAT YOU CAN DO
States and Communities Can:
■■ Know resistance trends in your region. 
■■ Coordinate local and regional infection tracking and control efforts. 
■■ Require facilities to alert each other when transferring patients with any infection. 
Healthcare CEOs, Medical Officers, and Other Healthcare Facility 
Leaders Can:
■■ Require and strictly enforce CDC guidance for infection detection, prevention, 
tracking, and reporting. 
■■ Make sure your lab can accurately identify infections and alert clinical and 
infection prevention staff when these bacteria are present. 
■■ Know infection and resistance trends in your facility and in the facilities  
around you. 
■■ When transferring a patient, require staff to notify the other facility about all 
infections.
■■ Join or start regional infection prevention efforts.
■■ Promote wise antibiotic use.
Healthcare Providers Can:
■■ Know when and types of drug-resistant infections are present in your 
facility and patients.
■■ Request immediate alerts when the lab identifies drug-resistant 
infections in your patients.
■■ Alert the other facility when you transfer a patient with a drug-resistant infection. 
■■ Protect patients from drug-resistant infections.
■■ Follow relevant guidelines and precautions at every patient encounter.
■■ Prescribe antibiotics wisely.
■■ Remove temporary medical devices such as catheters and ventilators as soon as no 
longer needed.
Patients and Their Loved Ones Can:
■■ Ask everyone, including doctors, nurses, other medical staff,  
and visitors, to wash their hands before touching the patient.
■■ Take antibiotics only and exactly as prescribed.
ONLINE RESOURCES
Resources CDC’s MRSA website 
www.cdc.gov/hai/mrsa
Prevention Guidelines for MRSA 
www.cdc.gov/hicpac/pubs.html













IN EXCESS MEDICAL COSTS PER YEAR
THREAT LEVEL
SERIOUS
This bacteria is a serious concern and requires prompt  
and sustained action to ensure the problem does not grow.
Streptococcus pneumoniae (S. pneumoniae, or pneumococcus) is the leading cause of bacterial pneumonia and meningitis in the United States. It also is a major 
cause of bloodstream infections and ear and sinus infections.
RESISTANCE OF CONCERN
S. pneumoniae has developed resistance to drugs in the penicillin and 
erythromycin groups. Examples of these drugs include amoxicillin and azithromycin 
(Zithromax, Z-Pak). S. pneumoniae has also developed resistance to less commonly 
used drugs.
PUBLIC HEALTH THREAT
Pneumococcal disease, whether or not resistant to antibiotics, is a major public 
health problem. Pneumococcal disease causes 4 million disease episodes and 
22,000 deaths annually. Pneumococcal ear infections (otitis media) are the 
most common type of pneumococcal disease among children, causing 1.5 
million infections that often result in antibiotic use. Pneumococcal pneumonia 
is another important form of pneumococcal disease. Each year, nearly 160,000 
children younger than 5 years old see a doctor or are admitted to the hospital 
with pneumococcal pneumonia. Among adults, over 600,000 seek care for or are 
hospitalized with pneumococcal pneumonia. Pneumococcal pneumonia accounts 
for 72% of all direct medical costs for treatment of pneumococcal disease.
In 30% of severe S. pneumoniae cases, the bacteria are fully resistant to one or 
more clinically relevant antibiotics. Resistant infections complicate treatment 
and can result in almost 1,200,000 illnesses and 7,000 deaths per year. Cases 
of resistant pneumococcal pneumonia result in about 32,000 additional doctor 
visits and about 19,000 additional hospitalizations each year. The excess costs 
associated with these cases are approximately $96 million. 
Invasive pneumococcal disease means that bacteria invade parts of the body that 
are normally sterile, and when this happens, disease is usually severe, causing 
hospitalization or even death. The majority of cases and deaths occur among adults 
50 years or older, with the highest rates among those 65 years or older. Almost 
everyone who gets invasive pneumococcal disease needs treatment in the hospital.
DRUG-RESISTANT
STREPTOCOCCUS PNEUMONIAE
FIGHTING THE SPREAD OF RESISTANCE
Pneumococcal conjugate vaccine (PCV) is an effective tool to prevent infections. Vaccine use has 
not only reduced the burden of invasive pneumococcal disease, but it has also reduced antibiotic 
resistance by blocking the transmission of resistant S. pneumoniae strains. From 2000–2009, PCV7 
provided protection against seven pneumococcal strains, and beginning in 2010 use of PCV13 
expanded that protection to 13 strains. Achieving high vaccination coverage and encouraging 
appropriate antibiotic use will slow the spread of pneumococcal resistance. Using the right 
antibiotic at the right time is crucial. 
WHAT CDC IS DOING
Through partnerships between CDC, state health departments, and universities, CDC is 
tracking S. pneumoniae through its Active Bacterial Core surveillance (ABCs). CDC is 
promoting appropriate antibiotic use among outpatient health care providers and the 
public through its Get Smart: Know When Antibiotics Work program. As part of this program, CDC 
hosts Get Smart About Antibiotic Week, an annual one week observance of the importance of 
appropriate antibiotic use and its impact on antibiotic resistance. CDC is also working with many 
partners in the U.S. to ensure that pneumococcal vaccines are available for children and that 
uptake is high.
WHAT YOU CAN DO
■■ Prevent infections by getting recommended vaccines and practicing  
good hand hygiene. 
■■ Take antibiotics exactly as the doctor prescribes. Do not skip doses.  
Complete the prescribed course of treatment, even when you start  
feeling better. 
■■ Only take antibiotics prescribed for you; do not share or use leftover antibiotics. 
■■ Do not save antibiotics for the next illness. Discard any leftover medication once the 
prescribed course of treatment is completed. 
■■ Do not ask for antibiotics when your doctor thinks you do not need them. 
The very young 
and senior adults 









Cases of antibiotic-resistant invasive disease per 100,000 persons,  
by age group and resistance profile — Active Bacterial Core surveillance
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Cases and deaths per 100,000 population  
by resistance profile — ABCs areas, 2000–2011
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Pneumococcal Vaccine Recommendations  
http://www.cdc.gov/vaccines/vpd-vac/pneumo/in-short-both.
htm#who 
Get Smart: Know When Antibiotics Work Program 
http://www.cdc.gov/getsmart/
Active Bacterial Core surveillance (ABCs) 
http://www.cdc.gov/abcs/index.html










CASES IN 2011 
(U.S.)
TUBERCULOSIS IS AMONG THE MOST COMMON INFECTIOUS DISEASES AND  
FREQUENT CAUSES OF DEATH WORLDWIDE
THREAT LEVEL
SERIOUS
This bacteria is a serious concern and requires prompt  
and sustained action to ensure the problem does not grow.
Tuberculosis (TB) is among the most common infectious diseases and a frequent cause of death worldwide. TB is caused by the bacteria Mycobacterium tuberculosis 
(M. tuberculosis) and is spread most commonly through the air. M. tuberculosis can affect any part of the body, but disease is found most often in the lungs. In most cases, TB is 
treatable and curable with the available first-line TB drugs; however, in some cases, M. tuberculosis can be resistant to one or more of the drugs used to treat it. Drug-resistant TB 
is more challenging to treat — it can be complex and requires more time and more expensive drugs that often have more side effects. Extensively Drug-Resistant TB (XDR TB) is 
resistant to most TB drugs; therefore, patients are left with treatment options that are much less effective. The major factors driving TB drug resistance are incomplete or wrong 
treatment, short drug supply, and lack of new drugs. In the United States most drug-resistant TB is found among persons born outside of the country.  
RESISTANCE OF CONCERN
■■ Resistance to antibiotics used for standard therapy
■■ Resistance to isoniazid (INH) 
■■ Some TB is multidrug-resistant (MDR), showing resistance to at least INH 
and rifampicin (RMP), two essential first-line drugs
■■ Some TB is XDR TB, defined as MDR TB plus resistance to any 
fluoroquinolone and to any of the three second-line injectable drugs  
(i.e., amikacin, kanamycin, capreomycin)
PUBLIC HEALTH THREAT
Of a total of 10,528 cases of TB in the United States reported in 2011, antibiotic 
resistance was identified in 1,042, or 9.90%, of all TB cases.
  Number of cases
Cases per 100,000 
U.S. population
Percent of all TB 
cases in U.S.
Any first-line resistance 1,042 0.33 10%
INH resistance 740 0.24 7%
MDR TB 124 0.04 1%
XDR TB 6 0.0019 <1%
Deaths caused by antibiotic-
resistant TB
50
For more information about data methods and references, please see technical appendix.
DRUG-RESISTANT
TUBERCULOSIS
Health care providers can help prevent drug-resistant TB by quickly suspecting 
and diagnosing cases, following recommended treatment guidelines, monitoring 
patients’ response to treatment, and ensuring therapy is completed. Additional 
drug-resistant TB prevention measures include implementing effective infection 
control procedures that help limit exposure to known drug-resistant TB patients in 
settings such as hospitals, prisons, or homeless shelters.  
WHAT CDC IS DOING
CDC conducts ongoing surveillance for drug-resistant TB in all 50 states and 
the District of Columbia using the National Tuberculosis Surveillance System 
(NTSS). The TB Genotyping Information Management System (TBGIMS), 
a Web-based system designed to improve access and dissemination of 
genotyping information nationwide, complements the ongoing surveillance 
for drug- resistant TB by linking genotyping results to surveillance data. In 2009, 
CDC implemented the Molecular Detection of Drug Resistance Service (MDDR), a 
national clinical referral service which provides rapid confirmation of MDR and 
XDR TB. Molecular drug-resistant testing enhances but does not replace culture or 
conventional drug-susceptibility testing. 
Other CDC activities directed at preventing spread of drug-resistant TB include 
funding of five TB Regional Training and Medical Consultation Centers (RTMCCs) 
from 2013–2017. The RTMCCs are regionally assigned to cover all 50 states and the 
U.S. territories. One of the primary purposes of each RTMCC is to provide medical 
consultation to TB programs and medical providers, particularly for complex, drug-
resistant cases. Additionally, the RTMCCs offer trainings that provide information 
on diagnosing and treating drug-resistant TB.
Additionally, CDC international activities include studies to improve first and 
second line antibiotic use in patients with drug-resistant TB.
FIGHTING THE SPREAD OF RESISTANCE
Antibiotic resistance 
occurs most often among 
those aged 25-44. 
Cases of Antibiotic-resistant TB by Age Group, 2011
The number of TB 
cases with isoniazid 
resistance or any 
first-line antibiotic 
resistance declined 
from 2003 through 
2011. However, both 
types of resistance 
had increases in 
cases in 2011. 
Multidrug-resistant 
TB has been fairly 
consistent over this 
same time period
























MICROORGANISMS WITH  
A THREAT LEVEL OF CONCERNING
Vancomycin-resistant Staphylococcus aureus (VRSA)
Erythromycin-resistant Group A Streptococcus
Clindamycin-resistant Group B Streptococcus
THREAT LEVEL
CONCERNING
These bacteria are concerning, and 





4 STATES SINCE 2002IN
CASES
SOME STAPHYLOCOCCUS STRAINS ARE RESISTANT TO VANCOMYCIN  
LEAVING FEW OR NO TREATMENT OPTIONS
THREAT LEVEL
CONCERNING
This bacteria is concerning, and careful monitoring  
and prevention action are needed.
Staphylococcus aureus is a common type of bacteria that is found on the skin. During medical procedures when patients require 
catheters or ventilators or undergo surgical procedures, Staphylococcus aureus can enter the body and cause infections. When 
Staphylococcus aureus becomes resistant to vancomycin, there are few treatment options available because vancomycin-resistant  
S. aureus bacteria identified to date were also resistant to methicillin and other classes of antibiotics.
RESISTANCE OF CONCERN
In rare cases, CDC has identified Staphylococcus aureus that is resistant to 
vancomycin, the antibiotic most frequently used to treat serious S. aureus 
infections. 
PUBLIC HEALTH THREAT
A total of 13 cases of vancomycin-resistant Staphylococcus aureus (VRSA) have 
been identified in the United States since 2002.
VRSA infection continues to be a rare occurrence. A few existing factors seem to 
predispose case patients to VRSA infection, including: 
■■ Prior MRSA and enterococcal infections or colonization 
■■ Underlying conditions (such as chronic skin ulcers and diabetes) 


















13 N/A N/A 0 N/A
For more information about data methods and references, please see technical appendix.
VANCOMYCIN-RESISTANT
STAPHYLOCOCCUS AUREUS
WHAT CDC IS DOING
■■ Confirming cases after being notified by local public health 
authorities.
■■ Providing states and facilities with outbreak support such as staff 
expertise, prevention guidelines, tools, and lab assistance. 
■■ Developing tests and prevention recommendations to control drug-
resistant infections.
■■ Helping medical facilities improve antibiotic prescribing practices.
WHAT YOU CAN DO
States and Communities Can:
■■ Know resistance trends in your region. 
■■ Coordinate local and regional infection tracking and 
control efforts. 
■■ Require facilities to alert each other when transferring patients with 
any infection.
Healthcare CEOs, Medical Officers, and Other Healthcare 
Facility Leaders Can:
■■ Require and strictly enforce CDC guidance for infection detection, 
prevention, tracking, and reporting. 
■■ Make sure your lab can accurately identify infections, and alert clinical 
and infection prevention staff when these bacteria are present. 
■■ Know infection and resistance trends in your facility and in the 
facilities around you. 
■■ When transferring a patient, require staff to notify the other facility 
about all infections. 
■■ Join or start regional infection prevention efforts.
■■ Promote wise antibiotic use.
FIGHTING THE SPREAD OF RESISTANCE
Healthcare Providers Can:
■■ Know when and what types of drug-resistant infections are 
present in your facility and patients.
■■ Request immediate alerts when the lab identifies drug-
resistant infections in your patients.
■■ Alert the other facility when you transfer a patient with a drug-
resistant infection. 
■■ Treat wounds aggressively.
■■ Use vancomycin responsibly.
■■ Protect patients from drug-resistant infections.
■● Follow relevant guidelines and precautions at every patient 
encounter.
■● Prescribe antibiotics wisely.
■● Remove temporary medical devices such as catheters and 
ventilators as soon as no longer needed.
Patients and Their Loved Ones Can:
■■ Ask everyone, including doctors, nurses, other medical  
staff, and visitors, to wash their hands before touching  
the patient.
■■ Take antibiotics only and exactly as prescribed.
ONLINE RESOURCES
Vancomycin-Intermediate/Resistant Staphylococcus (VISA/
VRSA) in Healthcare Settings  
http://www.cdc.gov/HAI/organisms/visa_vrsa/visa_vrsa.html 







DRUG-RESISTANT GROUP A  
STREP INFECTIONS PER YEAR
160
DEATHS
GROUP A STREP IS THE LEADING CAUSE OF  
NECROTIZING FASCIITIS (“FLESH-EATING” DISEASE)
1–2.6 MILLION STREP THROAT  INFECTIONS PER YEARTHREAT LEVEL
CONCERNING
This bacteria is concerning, and careful monitoring  
and prevention action are needed.
Group A Streptococcus (GAS) causes many illnesses, including pharyngitis (strep throat), streptococcal toxic shock syndrome, necrotizing fasciitis 
(“flesh-eating” disease), scarlet fever, rheumatic fever, and skin infections such as impetigo.
RESISTANCE OF CONCERN
GAS has developed resistance to clindamycin and a category of drugs called macrolides. 
Macrolides include erythromycin, azithromycin and clarithromycin. GAS has also developed 
resistance to a less commonly used drug—tetracycline. Of these, resistance to erythromycin 
and the other macrolide antibiotics is of the most immediate concern.  
PUBLIC HEALTH THREAT
Each year in the United States, erythromycin-resistant, invasive GAS causes 1,300 illnesses 
and 160 deaths. 
GAS is a leading cause of upper respiratory tract infections such as strep throat. There 
are 1-2.6 million cases of strep throat in the U.S. each year. These bacteria are also the 
leading cause of necrotizing fasciitis, an invasive disease that can be fatal in 25%–35% 
of cases. Invasive disease means that bacteria invade parts of the body that are normally 
sterile. When this happens, disease is usually very severe, causing hospitalization or even 
death. Those at highest risk for invasive disease are the elderly, those with skin lesions, 
young children, people in group living situations such as nursing homes, and those with 
underlying medical conditions, such as diabetes. 
Penicillin is the recommended first-line treatment for GAS infections. Amoxicillin is a type 
of penicillin that is often used to treat strep throat. Currently, GAS is not resistant to 
treatment with penicillin. If resistance to penicillin emerges, it would severely compromise 
treatment of invasive GAS infections. For people who are allergic to penicillin, two of 
the alternative antibiotics, azithromycin and clarithromycin, can be used to treat strep 
throat. In fact, azithromycin is prescribed more commonly than penicillin. Of GAS bacterial 
samples tested at CDC from 2010 and 2011, 10% were erythromycin-resistant (and therefore 
resistant to other macrolides such as azithromycin and clarithromycin), while 3.4% were 
clindamycin-resistant. Increasing resistance to erythromycin will complicate treatment of 
strep throat, particularly for those who cannot tolerate penicillin.
A more current concern is the increase in bacteria that show the genetic potential for 
becoming resistant to clindamycin. Clindamycin has a unique role in treatment of severe 
GAS infections. For severe, life-threatening infections, like necrotizing fasciitis and toxic 
shock syndrome, a combination of penicillin and clindamycin is recommended for treatment. 
ERYTHROMYCIN-RESISTANT
GROUP A STREPTOCOCCUS
FIGHTING THE SPREAD OF RESISTANCE
Encouraging appropriate antibiotic use, including using the right antibiotic at the 
right time, and for the right amount of time, is crucial to preventing the spread 
of drug-resistant GAS. Doctors should adhere to the recommended antibiotics for 
treating GAS infections, including using penicillin or amoxicillin whenever possible.
WHAT CDC IS DOING
CDC has collaborated with the Infectious Diseases Society of America to update 
guidance on diagnosing strep throat and selecting antibiotics to treat it. These 
guidelines reinforce appropriate use of antibiotics for this common illness. CDC 
is also promoting appropriate antibiotic use among outpatient healthcare 
providers and the public through its Get Smart: Know When Antibiotics Work 
program. As part of this program, CDC hosts Get Smart About Antibiotics 
Week, an annual one-week observance of the importance of appropriate 
antibiotic use and its impact on antibiotic resistance. Through partnerships 
between CDC, state health departments, and universities, CDC is tracking GAS 
through Active Bacterial Core surveillance (ABCs). 
WHAT YOU CAN DO
■■ Prevent infections by practicing good hand hygiene. 
■■ Take antibiotics exactly as the doctor prescribes. Do not skip  
doses. Complete the prescribed course of treatment, even  
when you start feeling better. 
■■ Only take antibiotics prescribed for you. Do not share or use  
leftover antibiotics. 
■■ Do not save antibiotics for the next illness. Discard any leftover medication 
once the prescribed course of treatment is completed. 
■■ Do not ask for antibiotics when your doctor thinks you do not need them.
Rates of resistance to 
two core antibiotics 
continue to increase 
for group A strep.
Prevalence of erythromycin, clindamycin and tetracycline resistance  




Active Bacterial Core surveillance (ABCs) 
http://www.cdc.gov/abcs/index.html
Get Smart: Know When Antibiotics Work Program 
http://www.cdc.gov/getsmart/










7,600 DRUG-RESISTANT GROUP B STREP INFECTIONS 440 DEATHS
27,000
GROUP B STREP IS THE LEADING CAUSE OF  
SERIOUS BACTERIAL INFECTIONS IN NEWBORNS




This bacteria is concerning, and careful monitoring  
and prevention action are needed.
Group B Streptococcus (GBS) is a type of bacteria that can cause severe illnesses in people of all ages, ranging from bloodstream 
infections (sepsis) and pneumonia to meningitis and skin infections.
RESISTANCE OF CONCERN
GBS has developed resistance to clindamycin and erythromycin. GBS that are resistant 
to erythromycin will also be resistant to azithromycin. Recently, the very first cases with 
resistance to vancomycin have been detected among adults. These cases are extremely rare 
and also very concerning since vancomycin is the most commonly used drug for treatment of 
potentially resistant gram-positive infections in adults. Strains with decreasing responsiveness 
to treatment with penicillin drugs have been described but remain very rare. Resistance to 
clindamycin is of the most immediate clinical concern, although the other forms of resistance 
are worrisome.
PUBLIC HEALTH THREAT
Each year in the United States, clindamycin-resistant Group B Strep causes an estimated 
7,600 illnesses and 440 deaths.
In the United States, GBS is the leading cause of serious bacterial infections in newborns, 
including bloodstream infections, meningitis, and pneumonia. When these GBS infections 
occur in the first 7 days of life, they are known as early-onset disease. To prevent early-
onset disease in newborns, antibiotics are given during labor and delivery to mothers who 
test positive for GBS (tested at 35–37 weeks of pregnancy with a vaginal/rectal swab) and 
to those who have other risk factors for passing GBS to their newborns. 
GBS also is one of the most common causes of meningitis and other severe infections in 
infants from 7 days to 3 months old (late-onset disease). GBS is also an increasing cause 
of bloodstream infections, pneumonia, skin and soft tissue infections, and bone and joint 
infections in adults, especially among pregnant women, the elderly, and people with certain 
medical conditions such as diabetes.
CDC estimates from preliminary data that 27,000 cases of severe GBS disease, such as blood 
infections or meningitis, occurred in 2011, causing 1,575 deaths. Forty-nine percent of GBS 
isolates (samples) tested were erythromycin-resistant, and 28% were clindamycin-resistant. 
Although the incidence of early-onset disease has been decreasing, the proportion of GBS 
infections resistant to erythromycin and clindamycin has increased steadily since 2000. 
Resistance to the penicillin drug class could threaten the success of strategies to prevent 
early-onset disease and lead to treatment failures since penicillin drugs are the top choice 
for treating GBS. Additionally, the increasing resistance to recommended second-line drugs, 
clindamycin and erythromycin, limits prevention and treatment for patients with GBS who 
are allergic to penicillin. 
CLINDAMYCIN-RESISTANT GROUP B
STREPTOCOCCUS 
FIGHTING THE SPREAD OF RESISTANCE
Doctors should test all pregnant women for GBS at 35–37 weeks of pregnancy and 
adhere to the recommended antibiotics during labor and delivery for prevention of early-
onset disease. Broad efforts to promote appropriate use of antibiotics in outpatient and 
inpatient settings will also help minimize the spread of resistance among GBS bacteria.
WHAT CDC IS DOING
CDC, in collaboration with professional associations, has developed evidence-based 
Guidelines for the Prevention of Perinatal Group B Streptococcal Disease. These 
guidelines discuss diagnosis and management, and recommendations are provided 
regarding antibiotic choices and dosing. They also support GBS screening 
for all pregnant women at 35–37 weeks of pregnancy and use of antibiotics 
during labor and delivery to prevent newborn infection. Through partnerships 
between CDC, state health departments, and universities, CDC is tracking GBS 
through its Active Bacterial Core surveillance (ABCs). This program monitors 
antibiotic resistance and has contributed to the detection of the very first cases in the 
U.S. of vancomycin-resistant GBS, as well as tracking of susceptibility trends of other 
antibiotics important for treatment of GBS. CDC is promoting appropriate antibiotic use 
among outpatient health care providers and the public through its Get Smart: Know 
When Antibiotics Work program. 
WHAT YOU CAN DO
■■ Pregnant women should talk to their doctor or nurse about their GBS  
status and let them know of any medication allergies during a checkup.
■■ When women get to the hospital or birthing center for delivery, they  
should remind their doctor or nurse if they have GBS and if they are  
allergic to any medications.
■■ Practice appropriate antibiotic use whenever you see a doctor or are prescribed 
an antibiotic for any condition:
■● Take antibiotics exactly as the doctor prescribes. Do not skip doses. Complete 
the prescribed course of treatment, even when you start feeling better. 
■● Only take antibiotics prescribed for you. Do not share or use leftover 
antibiotics. 
■● Do not save antibiotics for the next illness. Discard any leftover medication 
once the prescribed course of treatment is completed. 
■● Do not ask for antibiotics when your doctor thinks you do not need them.
Group B strep 
continues to 
become more 
resistant to two 
major antibiotics, 
leaving those 
allergic to first 
line drugs in 
jeopardy.
Proportion of Group B Streptococcus isolates resistant  
to erythromycin and clindamycin— 
Active Bacterial Core surveillance (ABCs), 2000-2010*
*Most recent data available.
Early-onset 
group B strep 
disease has 
declined by 





Incidence of Early-Onset Disease Caused by Group B Streptococcus—
Active Bacterial Core surveillance (ABCs), 1989–2010




Group B Strep (GBS) 
http://www.cdc.gov/groupbstrep/about/index.html












National estimates of the number of Clostridium difficile (C. difficile) 
infections (CDI) requiring hospitalization or in already hospitalized 
patients were obtained from the data submitted through the 
Emerging Infections Program’s C. difficile surveillance in 2011, of 
34 counties in 10 U .S . states (http://www .cdc .gov/hai/eip/cdiff_techinfo .html) . During 
2011, a total of 15,452 CDI cases were identified across the participating sites . Data on 
hospitalization following CDI or at the time of infection were obtained for all cases from 
8 of 10 U .S . states and from a random sample of 33% from cases from the other 2 states . 
The sampled cases were used to estimate total number of hospitalizations in the 2 states 
where sampling was performed . The national estimates were made using 2011 population 
estimates from U .S . Census Bureau adjusting for age, gender and race distribution of 
the American population .1 Approximately 18% of cases were reported without a race 
value . Multiple imputation was used to estimate the missing race based on the data that 
are available and the results were summarized . The C. difficile attributable mortality was 
estimated from death certificate data .2 Trends on deaths related to C. difficile were obtained 
from the CDC’s National Center for Health Statistics .3 Estimates were rounded to two 
significant digits .
References
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J, Beldavs S, McDonald LC, Fridkin SK . Presented at the IDWeek 2012, Annual Meeting 
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2012 .
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difficile and Norovirus Among Gastroenteritis-Associated Deaths in the United States, 
1999-2007 . Clin Infect Dis . 2012 Jul;55(2):216–23 .
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National estimates of the number of healthcare-associated infections 
(HAIs) with Enterobacteriaceae, Pseudomonas aeruginosa, Candida, 
Acinetobacter, or Enterococci were obtained from a 2011 survey of 
11,282 patients in 183 hospitals in 10 different states, among whom 
452 were identified with at least one HAI for a total of 504 HAIs (some 
patients had >1 HAI) . 
Many assumptions were made in deriving national estimates, using 
these 452 patients, and adjusting for age and length of stay using 
the 2010 Nationwide Inpatient Sample (NIS), Healthcare Cost and 
Utilization Project (HCUP), Agency for Healthcare Research and 
Quality . For 2011, an estimated 647,985 patients had at least one HAI, 
resulting in an estimated 721,854 HAIs .1 481 pathogens were reported 
among the 504 HAIs detected; 50 K. pneumonia or K. oxytoca (9 .9%), 
47 E. coli (9 .3%), 46 Enterococci spp. (9 .1%), 36 P. aeruginosa (7 .1%), 34 
Candida spp. (6 .7%), 8 Acinetobacter spp. (1 .6%) . For each pathogen, the 
pathogen-specific annual estimate was obtained by multiplying this 
proportion (of all HAIs) by the national HAI estimate (721,854) . Next, 
the estimated no . of resistant infections was obtained by multiplying 
the respective pathogen-specific national estimate by the proportion 
of pathogens reported as non-susceptible to the antimicrobial 
of interest from other CDC data systems . For Enterobacteriaceae, 
Pseudomonas aeruginosa, Acinetobacter, and Enterococci this was CDC’s 
National Healthcare Safety Network and includes the mean percent 
non-susceptible across the device and procedure-associated HAIs 
reported during 2009–20102; see individual fact sheets in this report 
for percent resistance for each pathogen . 
For Candida by the proportion of Candida species testing non-
susceptible to fluconazole that were submitted to CDC for 
confirmatory testing as part of the Emerging Infections Program 
Surveillance of Candida bloodstream infections during 2008-2011 .3 In 
this program a total of 2,675 Candida species isolates associated with 
bloodstream infections were submitted as part of the EIP population-
based surveillance in 2 US cities, azole resistance was identified in 165 
cases, or 7% . 
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The number of deaths attributable to the antimicrobial-resistant healthcare-associated 
infection was determined by multiplying the estimated number of resistant infections by 
6 .5%, an overall estimate of attributable mortality from antibiotic-resistant hospital-onset 
infections previously determined .4 This estimate accounts for the overall distribution of 
the different types of infections commonly caused by antibiotic-resistant pathogens in 
hospitalized patients and is generally much lower than the crude mortality observed in 
many of these patients owing to their severe underlying disease status . Definitions of 
multidrug resistance used in this analysis are published elsewhere .2 The proportion of U .S . 
hospitals reporting carbapenem-resistant Enterobacteriaceae was derived as reported 
elsewhere .5 Estimates were rounded to two significant digits .
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Estimates of the number of gonococcal infections with any resistance 
pattern, reduced susceptibility to cephalosporins or azithromycin, 
or resistance to tetracycline are reported . They are derived by 
multiplying an estimate of the annual number of gonococcal 
infections in the United States1 by the prevalence of reduced 
susceptibility or resistance among urethral Neisseria gonorrhoeae 
isolates collected and tested by the Gonococcal Isolate Surveillance Project (GISP)  
during 2011 .2 
Many assumptions were made in deriving the estimates . Data from the National Health 
and Nutrition Examination Survey (NHANES) provided accurate gonorrhea prevalence 
estimates, although NHANES only measures urogenital infections and does not include 
oropharyngeal or rectal infections . The average duration of infection, used to calculate 
incidence, was based on expert opinion, due to an absence of published data . Also, 
estimates of resistance in GISP are nationally representative . However, compared to the 
regional distribution of reported gonococcal infections, GISP relatively over-samples 
patients from the West Coast, where resistance has traditionally first emerged in the United 
States . The Clinical Laboratory Standards Institute categorizes susceptibility to cefixime 
and ceftriaxone as minimum inhibitory concentrations (MICs) ≤0 .25 µg/ml .3 For this 
analysis, isolates with cefixime MICs ≥0 .25 µg/ml were considered to have reduced cefixime 
susceptibility, and isolates with ceftriaxone MICs ≥0 .125 µg/ml were considered to have 
reduced ceftriaxone susceptibility . An azithromycin MIC ≥2 .0 µg/ml was considered to have 
reduced azithromycin susceptibility, and a tetracycline MIC ≥2 .0 µg/ml was considered 
resistant . Resistance to any antimicrobial includes resistance to penicillin (MIC ≥ 2 µg/ml), 
tetracycline, ciprofloxacin (MIC ≥ 1µg/ml), or spectinomycin (MIC ≥ 128 µg/ml), or reduced 
susceptibility to the cephalosporins or azithromycin .
GISP, established in 1986, is a sentinel surveillance system with partners that include CDC, 
sexually transmitted disease clinics at 25–30 sentinel sites, and 5 regional laboratories in the 
United States .4 Gonococcal isolates are collected from up to the first 25 men diagnosed with 
gonococcal urethritis at each sentinel site each month . Antimicrobial susceptibility testing 
is performed using agar dilution for a panel of antimicrobials that includes penicillin, 
tetracycline, ciprofloxacin, spectinomycin, cefixime, ceftriaxone, and azithromycin . 
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Estimates of the number of illnesses and deaths from infections with 
Campylobacter resistant to ciprofloxacin or azithromycin are reported . 
They were derived by multiplying an estimate of the annual number 
of Campylobacter illnesses or deaths in the United States1 by the 
average prevalence of resistance among Campylobacter tested by the 
National Antimicrobial Resistance Monitoring System (NARMS) during the years 2009–2011 . 
Resistance breakpoints from the NARMS 2011 Human Isolates Report were used .2 
Many assumptions were made in deriving the estimates . The estimated number of illnesses 
from resistant Campylobacter was divided by the U .S . population and multiplied by 100,000 
to calculate the estimated number of illnesses from resistant infections per 100,000 
people . The U .S . population in 2006 (approximately 299 million people) was used for the 
calculations because the estimated number of Campylobacter illnesses in the United States 
was based on this population .1 The sentinel county survey data displayed in Figure 1 was 
previously reported .3
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Technical Appendix
Drug-Resistant Non-Typhoidal Salmonella 
Methods
Estimates of the number of illnesses and deaths from infections with 
non-typhoidal Salmonella resistant to ceftriaxone, resistant or partially 
resistant to ciprofloxacin, or resistant to five or more antibiotic classes 
are reported . They were derived by multiplying an estimate of the 
annual number of non-typhoidal Salmonella illnesses or deaths in the 
United States1 by the average prevalence of resistance among non-typhoidal Salmonella 
isolates tested by the National Antimicrobial Resistance Monitoring System (NARMS) during 
the years 2009–2011 . Resistance breakpoints from the NARMS 2011 Human Isolates Report 
were used .3 For ciprofloxacin, isolates with intermediate susceptibility results (minimum 
inhibitory concentration of 0 .12–0 .5 µg/ml) were considered partially resistant .
Many assumptions were made in deriving the estimates . The estimated number of illnesses 
from resistant Salmonella was divided by the U .S . population and multiplied by 100,000 
to calculate the estimated number of illnesses from resistant Salmonella per 100,000 
population . The U .S . population in 2006 (approximately 299 million people) was used for 
the calculations because the estimated number of non-typhoidal Salmonella illnesses in 
the United States was based on this population .1 The methods used to estimate the direct 
medical costs for Salmonella infections were previously reported .2
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Technical Appendix
Drug-Resistant Salmonella Serotype Typhi
Methods
An estimate of the number of illnesses and deaths from Salmonella 
serotype Typhi resistant or partially resistant to ciprofloxacin was 
derived by multiplying an estimate of the annual number of illnesses 
or deaths from typhoid fever in the United States1 by the average 
prevalence of ciprofloxacin resistance or partial resistance among 
Salmonella Typhi isolates tested by the National Antimicrobial Resistance Monitoring 
System (NARMS) during 2009–2011 . Resistance breakpoints from the NARMS 2011 Human 
Isolates Report were used .2 For ciprofloxacin, isolates with intermediate susceptibility 
results (minimum inhibitory concentration of 0 .12–0 .5 µg/ml) were considered partially 
resistant .
 Many assumptions were made in deriving the estimates . The estimated number of illnesses 
from ciprofloxacin resistant or partially resistant Salmonella Typhi was divided by the U .S . 
population and multiplied by 100,000 to calculate the estimated number of illnesses from 
resistant or partially resistant infections per 100,000 people . The U .S . population in 2006 
(approximately 299 million people) was used for the calculations because the estimated 
number of typhoid fever illnesses in the United States was based on this population . 
Worldwide case estimates3 and pre-antibiotic era mortality4 are from published sources . 
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Estimates of the number of illnesses and deaths from infections with 
Shigella resistant to azithromycin or ciprofloxacin are reported . They 
were derived by multiplying an estimate of the annual number of 
Shigella illnesses or deaths in the United States1 by the prevalence 
of resistance among Shigella tested by the National Antimicrobial 
Resistance Monitoring System (NARMS) in 2011, the year azithromycin testing began . 
Resistance breakpoints from the NARMS 2011 Human Isolates Report were used .2 As 
clinical azithromycin breakpoints have not been established for Shigella, the values used 
here were based on epidemiological cut-off values used in the NARMS report . Isolates with 
azithromycin minimal inhibitory concentrations of ≥32 µg/ml were considered resistant .
Many assumptions were made in deriving these estimates . The estimated number of 
illnesses from resistant Shigella was divided by the U .S . population and multiplied by 
100,000 to calculate the estimated number of illnesses from resistant infections per 
100,000 people . The U .S . population in 2006 (approximately 299 million people) was  
used for the calculations because the estimated number of Shigella illnesses in the United 
States was based on this population .1 The sentinel county survey data displayed were 
previously reported .3,4,5
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Methicillin-Resistant Staphylococcus aureus (MRSA) 
Methods
National estimates of the number of invasive MRSA healthcare-
associated infections (HAIs) were derived from the Emerging Infection 
Program/Active Bacterial Core Surveillance1 for Invasive MRSA using 
data reported for infections occurring during 2011 (http://www .
cdc .gov/abcs/reports-findings/surv-reports .html) . During 2011, 
4,872 reports of invasive MRSA (isolates of MRSA cultured from a normally sterile site and 
identified by a participating clinical laboratory) were received from the 9 participating 
program sites (population of 19,393,677) . Reports include both healthcare-associated 
infections and community-associated infections, but are limited to invasive infections 
(approximately 85% are bloodstream infections) .
Estimates were made using National Center for Health Statistics bridged-race vintage 2011 
post-censal file and U .S . renal data systems, adjusting for race, age, gender, and receipt 
of dialysis . Mortality includes all-cause mortality during hospitalization, and estimates 
were adjusted in similar fashion as infection estimates . Approximately 18% of cases were 
reported without a race value, multiple imputation was used to estimate the missing race 
based on the data that are available and the results were summarized . Regarding device 
and procedure-associated infections with MRSA, the proportion of facilities reporting 
at least one S. aureus HAI reported as MRSA for each HAI type was obtained from CDC’s 
National Healthcare Safety Network Antimicrobial Resistance Report 2009–2010 .2 Estimates 
were rounded to two significant digits .
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Vancomycin resistant S. aureus (VRSA) have been a nationally 
notifiable condition since 2004 .1 The national estimate of the number 
of VRSA cases is derived from individual case reports and confirmation 
at the Centers for Disease Control and Prevention (CDC) . All 
reported VRSA are submitted to CDC for confirmatory antimicrobial 
susceptibility with reference broth microdilution .2 Vancomycin resistance in S. aureus is 
defined as an MIC ≥ 16 ug/ ml . All isolates meeting this criterion are further characterized 
with PCR to detect known resistance mechanisms . All 13 U .S . VRSA identified to date have 
carried the vanA resistance determinant .3
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Trends in the incidence of antibiotic-resistant invasive pneumococcal 
disease per 100,000 persons are from Active Bacterial Core 
surveillance (ABCs), which is part of CDC’s Emerging Infections 
Program (EIP) network.1  ABCs conducts surveillance for invasive 
bacterial infections, including Streptococcus pneumoniae, at 10 sites 
located throughout the United States representing a population of approximately 30 
million persons. Isolates are collected on ≥90% of all cases (approximately 3200 isolates 
per year) and sent to reference laboratories for susceptibility testing to eighteen different 
antibiotics using Clinical and Laboratory Standards Institute (CLSI) methods. Estimates of 
invasive pneumococcal disease are also from ABCs.2
Estimates of the burden of antibiotic resistant pneumococcal disease are derived from three 
sources. First, numbers of cases were estimated by applying the rate for full resistance to 
clinically relevant drugs (i.e. penicillin, ceftriaxone, cefotaxime, erythromycin, levofloxacin, 
tetracycline, trimethoprim/sulfamethoxazole) in 2011 (30%) to estimates of cases of all  
S. pneumoniae infections (4 million) as estimated by Huang and colleagues.3 Numbers of 
deaths were estimated by applying the rate of full resistance to a clinically relevant drug 
(33%) to the total number of deaths from pneumococcal disease.3  Excess pneumococcal 
pneumonia visits, hospitalizations, and costs were estimated using the previous overall 
burden estimates3 but consideration of the burden of disease that would have occurred in 
the absence of resistance to penicillin, erythromycin, and levofloxacin.4 
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Erythromycin-Resistant Group A Streptococcus
Methods
Estimates of the proportion of GAS isolates resistant to erythromycin, 
clindamycin and tetracycline are from isolates collected through 
Active Bacterial Core surveillance (ABCs), which is part of CDC’s 
Emerging Infections Program (EIP) network .1 ABCs conducts 
surveillance for invasive bacterial infections, including GAS, at 10 
sites located throughout the United States representing a population of approximately 32 
million people . Isolates are collected on ~80% of all cases (approximately ~1000 isolates 
per year) and sent to reference laboratories for susceptibility testing to twelve different 
antibiotics using Clinical and Laboratory Standards Institute (CLSI) methods . 
Cases and deaths were estimated by applying 2011 resistant rate to erythromycin (10%, see 
Strep Group A Streptococcus pathogen page) to total cases (13300) and total deaths (1,550) 
reported in the 2011 report of the Active Bacteria Core surveillance (ABCs) .2
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Technical Appendix
Clindamycin-Resistant Group B Streptococcus
Methods
Estimates of the proportion of GBS isolates resistant to erythromycin 
and clindamycin are from isolates collected through Active Bacterial 
Core surveillance (ABCs), which is part of CDC’s Emerging Infections 
Program (EIP) network .1 ABCs conducts surveillance for invasive 
bacterial infections, including GBS, at 10 sites located throughout 
the United States representing a population of approximately 32 million persons . Isolates 
are collected currently from 7 of these states, from ~85% of the cases in these states 
(approximately ~1500 isolates per year) and sent to reference laboratories for susceptibility 
testing to twelve different antibiotics using Clinical and Laboratory Standards Institute 
(CLSI) methods . Estimates of severe disease are also from ABCs .2
Cases and deaths were estimated by applying the 2010 overall resistant rate to clindamycin 
(28%) from the ABCs antimicrobial susceptibilities report3 to total cases (27,000) and total 
deaths (1,575) reported in the 2011 ABCs GBS surveillance report .2
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GLOSSARY
Active Bacterial Core surveillance (ABCs): A core component of CDC’s Emerging 
Infections Programs network (EIP), a collaboration between CDC, state health departments, 
and universities . ABCs is an active laboratory- and population-based surveillance system 
that tracks invasive bacterial pathogens of public health importance . It currently operates 
among 10 EIP sites across the United States, representing a population of approximately 
41 million persons . At this time, ABCs conducts surveillance for six pathogens: group A 
and group B Streptococcus (GAS, GBS), Haemophilus influenzae, Neisseria meningitidis, 
Streptococcus pneumoniae, and methicillin-resistant Staphylococcus aureus (MRSA) .
Adverse drug event: When therapeutic drugs (example, antibiotics) have harmful effects; 
when someone has been harmed by a medication .
Aminoglycoside: A type of antibiotic that destroys the functioning of gram-negative 
bacteria . Increased resistance to aminoglycosides has made them less useful .
Antibiotic: Type of medicine made from mold or bacteria that kills or slows the growth of 
other bacteria . Examples include penicillin and streptomycin .
Antibiotic class: A grouping of antibiotics that are similar in how they work and how they 
are made .
Antibiotic growth promotion: Giving farm animals antibiotics to increase their size in 
order to produce and sell more meat .
Antibiotic resistance: The result of bacteria changing in ways that reduce or eliminate the 
effectiveness of antibiotics . Antibiotic resistance is one type of antimicrobial resistance .
Antibiotic stewardship: Coordinated efforts and programs to improve the use of 
antimicrobials . For example, facilities with antibiotic stewardship programs have made 
a commitment to always use antibiotics appropriately and safely—only when they are 
needed to prevent or treat disease, and to choose the right antibiotics and to administer 
them in the right way in every case .
Antimicrobial: A general term for the drugs, chemicals, or other substances that either 
kill or slow the growth of microorganisms . Among the antimicrobial agents in use today 
are antibacterial drugs (which kill bacteria), antiviral agents (which kill viruses), antifungal 
agents (which kill fungi), and antiparisitic drugs (which kill parasites) .
Antimicrobial resistance: The result of microorganisms changing in ways that reduce 
or eliminate the effectiveness of drugs, chemicals, or other agents used to cure or 
prevent infections . In this report, the focus is on antibiotic resistance, which is one type of 
antimicrobial resistance .
Azithromycin: A macrolide antibiotic used to treat infections caused by gram-positive 
bacteria and infections such as respiratory tract and soft-tissue infections .
Azoles: A large class of drugs developed to treat fungal infections .
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Bacteria: Single-celled organisms that live in and around us . Bacteria can be helpful,  
but in certain conditions can cause illnesses such as strep throat, ear infections, and 
bacterial pneumonia .
Bacteriology: The study of bacteria .
Beta (β)-lactamase enzyme: A chemical produced by certain bacteria that can destroy 
some kinds of antibiotics .
Broad-spectrum antibiotic: An antibiotic that is effective against a wide range of bacteria .
Carbapenem: A type of antibiotic that is resistant to the destructive beta-lactamase 
enzyme of many bacteria . Carbapenems are used as a last line of defense for many bacteria, 
but increased resistance to carbapenems has made them less useful . 
Cefixime: A cephalosporin antibiotic that is resistant to the destructive beta-lactamase 
enzyme of many bacteria .
Ceftriaxone: A cephalosporin antibiotic that is resistant to the destructive beta-lactamase 
enzyme of many bacteria .
Cephalosporin: Cephalosporins are a class of antibiotics containing a large number of 
drugs . Some more recently developed cephalosporins are resistant to the destructive beta-
lactamase enzyme produced by many bacteria . 
Ciprofloxacin: A broad-spectum fluoroquinolone antibiotic that is important in treating 
serious bacterial infections, especially when resistance to older antibiotic classes is 
suspected .
Clindamycin: An antibiotic used to treat certain types of bacterial infections, including 
infections of the lungs, skin, blood, female reproductive organs, and internal organs . 
Conjugate vaccine: A vaccine in which an antigen is attached to a carrier protein from the 
same microorganism . This approach enhances the immunological response to the vaccine 
and thereby enhances the overall effectiveness of the vaccine .
Echinocandins: A class of drugs developed to treat fungal infections .
EIP: The Emerging Infections Program network is a national resource for surveillance, 
prevention, and control of emerging infectious diseases . It was established in 1995 . The 
EIP is a network of 10 state health departments and their collaborators in local health 
departments, academic institutions, other federal agencies, and public health and clinical 
laboratories; infection preventionists; and healthcare providers . 
Endogenous flora: Bacteria that naturally reside in or on the body .
Epidemiology: The study of diseases to find out who is affected, how disease is spread, 
trends in illnesses and deaths, what behaviors or other risk factors might put a person 
at risk, and other information that can be used to develop prevention strategies . 
Epidemiologists use surveys and surveillance systems to track illnesses, and they often 
investigate disease outbreaks .
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Erythromycin: An antibiotic used to treat certain infections caused by bacteria, such as 
bronchitis, diphtheria, Legionnaires’ disease, pertussis (whooping cough), pneumonia, 
rheumatic fever, sexually transmitted diseases, and infections of the ear, intestine, lung, 
urinary tract, and skin . It is also used before some surgery or dental work to prevent 
infection .
Extended-spectrum antibiotic: An antibiotic that has been chemically modified to attack 
additional types of bacteria, usually those that are gram-negative .
Extensively drug-resistant (XDR): Resistance to nearly all drugs that would be considered 
for treatment . Exact definitions for XDR differ for each type of bacteria . 
Fluconazole: An antifungal drug in the azole class . 
Fluoroquinolones: Broad-spectrum antibiotics that play an important role in treatment 
of serious bacterial infections, especially hospital-acquired infections and others in 
which resistance to older antibacterial classes is suspected . Increasing resistant to 
fluoroquinolones is making them less effective . 
Fungus: A single-celled or multicellular organism . Fungi can be opportunistic pathogens 
(such as aspergillosis, candidiasis, and cryptococcosis) that cause infections in people 
with compromised immune systems, such as cancer patients, transplant recipients, and 
people with HIV/AIDS . Fungi can also be or pathogens (such as the endemic mycoses, 
histoplasmosis and coccidioidomycosis, and superficial mycoses) that cause infections in 
healthy people . Fungi are used to develop antibiotics, antitoxins, and other drugs used to 
treat various diseases .
GISP: The Gonococcal Isolate Surveillance Project was established in 1986 to monitor 
U .S . trends in antimicrobial susceptibilities of strains of Neisseria gonorrhoeae, the type 
of bacteria that causes gonorrhea . The goal of GISP is to establish a rational basis for the 
selection of drugs used to treat gonorrhea . GISP is a collaborative project between selected 
sexually transmitted disease clinics, five regional laboratories, and CDC . 
HAIs: Healthcare-associated infections are those that occur in hospitals, outpatient clinics, 
nursing homes, and other facilities where people receive care .
Hand hygiene: The practice of cleaning hands . This practice protects against infection  
and illness .
Hypervirulent: Increased ability to cause severe disease, relapse rates, and death . 
Invasive disease: A disease that can spread within the body to healthy tissue .
Isolate/bacterial isolate: A pure culture or sample of bacteria used to study their 
properties .
Isoniazid (INH): A first-line drug used to treat tuberculosis . Strains of tuberculosis resistant 
to INH and rifampin are considered to be multidrug resistant . 
Macrolide: A type of antibiotic used to treat infections caused by gram-positive bacteria 
and infections such as respiratory tract and soft-tissue infections . Macrolides are often used 
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in people allergic to penicillin, but resistance to macrolides is increasing and has made 
them less useful . 
Methicillin: An antibiotic derived from penicillin . It was previously used to treat bacteria 
such as Staphylococcus aureus. 
Microbiology: The study of microorganisms . 
Microorganism: Organisms so small that a microscope is required to see them . This term 
includes bacteria, fungi, parasites, and viruses . 
Morbidity: The number of people who are infected with a specified illness in a given  
time period .
Mortality: The number of people who die in a given time from a specified illness .
MRSA: Methicillin-resistant Staphylococcus aureus is used to describe any strain of S. aureus 
that is resistant to all types of penicillin (not just methicillin) as well as cephalosporin .
Multidrug-resistant (MDR): Microorganisms that are resistant to multiple classes of 
antimicrobials . The exact number of drugs that a microorganism is resistant to varies 
depending on the infection or pathogen .
NARMS: The National Antimicrobial Resistance Monitoring System monitors antimicrobial 
resistance in foodborne and other enteric bacteria, including Salmonella, Campylobacter, 
Shigella, Escherichia coli O157, and Vibrio (non-V. cholerae). NARMS is a collaboration among 
CDC, the U .S . Food and Drug Administration (FDA), the U .S . Department of Agriculture 
(USDA), and state and local health departments . 
Narrow-spectrum antibiotic: An antibiotic that is active against a limited range of 
bacteria .
NHSN: CDC’s National Healthcare Safety Network is the nation’s most widely used 
healthcare-associated infection tracking system . NHSN provides facilities, states, regions, 
and the nation with data needed to identify problem areas, measure progress of 
prevention efforts, and ultimately eliminate healthcare-associated infections . In addition, 
NHSN allows healthcare facilities to track blood safety errors and important healthcare 
process measures such as healthcare personnel influenza vaccine status and infection 
control adherence rates . 
Outbreak: When a group of people develop the same illness around the same time, 
and the number of people affected is higher than normal . Outbreak investigations are 
conducted to identify what exposure the affected people had in common . 
Pan drug-resistance (PDR): Resistance to all drugs that would be considered for treatment . 
Exact definitions for PDR differ for each bacteria .
Penicillins: A class of antibiotics including amoxicillin, methicillin, piperacillin and other 
drugs based on the first true antibiotic discovered in 1928 by Dr . Alexander Fleming . 
Increased resistance has made many types of penicillins less useful . 
Pneumonia: An inflammatory condition of the lungs affecting primarily the microscopic air 
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sacs known as alveoli . It is usually caused by infection with viruses or bacteria, and typical 
symptoms include a cough, chest pain, fever, and difficulty breathing .
Reservoir: A person, animal, insect, plant, or other host that is carrying a pathogen (for 
example, bacteria or fungi) that causes infectious diseases . Some pathogens have animal 
reservoirs (to survive, they need animal hosts) . Others pathogens have human reservoirs (to 
survive, they need human hosts) .
Resistant bacteria: Microorganisms that have changed in ways that reduce or eliminate 
the effectiveness of drugs, chemicals, or other agents to cure or prevent infections .
Rifampin: A first-line drug used to treat tuberculosis . Strains of tuberculosis resistant to 
isoniazid (INH) and rifampin (RMP) are considered to be multidrug resistant . 
Strain/bacterial strain: A strain is a genetic variant or subtype of a microorganism (for 
example, a flu strain is a subtype of the flu virus) . Some strains of bacteria are resistant to 
antibiotics, and others are not . When bacteria become resistant to antibiotics, they can 
share their resistance with other bacteria to create new resistant bacterial strains .
Superinfection: An infection following a previous infection, especially when caused by 
microorganisms that are resistant or have become resistant to the antibiotics used earlier .
Surveillance: The ongoing systematic collection and analysis of data . Surveillance systems 
that monitor infectious diseases provide data that can be used to develop actions to 
prevent infectious diseases .
Susceptible bacteria: When antibiotics are effective at killing or stopping the growth of a 
certain bacteria, the bacteria is known as susceptible to antibiotics . Susceptible infections 
are infections that can be treated effectively with antibiotics .
Systemic agents: Drugs that travel through the bloodstream and reach cells throughout 
the body .
Tetracyclines: A class of broad-spectrum antibiotics including tetracycline, doxycycline, 
minocycline, and other drugs . Increased resistance has made many types of tetracyclines 
less useful . 
Vaccine: A product that produces immunity in a person’s body and therefore protects them 
from an infectious disease . Vaccines are administered through shots, by mouth, and by 
aerosol mist . 
Vancomycin: A drug that is frequently used to treat methicillin-resistant Staphylococcus 
aureus infections and that is also effective against other bacteria . 
Virus: A strand of DNA or RNA in a protein coat that must get inside a living cell to grow 
and reproduce . Viruses cause many types of illness . For example, varicella virus causes 
chickenpox, and the human immunodeficiency virus (HIV) causes acquired immune 
deficiency syndrome (AIDS) .
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